WO2019023504A1 - Anticorps anti-tigit - Google Patents

Anticorps anti-tigit Download PDF

Info

Publication number
WO2019023504A1
WO2019023504A1 PCT/US2018/043968 US2018043968W WO2019023504A1 WO 2019023504 A1 WO2019023504 A1 WO 2019023504A1 US 2018043968 W US2018043968 W US 2018043968W WO 2019023504 A1 WO2019023504 A1 WO 2019023504A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
antibody
amino acid
tigit
acid sequence
Prior art date
Application number
PCT/US2018/043968
Other languages
English (en)
Inventor
Anthony Cooper
Christophe Queva
Sofie DENIES
Catherine HOOFD
Julie CUENDE
Gregory DRIESSENS
Florence LAMBOLEZ
Original Assignee
Iteos Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BE2017/5535A external-priority patent/BE1025333B1/fr
Priority to KR1020207005664A priority Critical patent/KR20200100589A/ko
Priority to EA202090309A priority patent/EA202090309A1/ru
Priority to CA3070791A priority patent/CA3070791A1/fr
Priority to SG11202000660QA priority patent/SG11202000660QA/en
Priority to BR112020001499-0A priority patent/BR112020001499A2/pt
Priority to US16/634,506 priority patent/US20200407445A1/en
Priority to ES18750302T priority patent/ES2812236T3/es
Priority to CN201880048693.8A priority patent/CN110997720A/zh
Priority to JP2020527852A priority patent/JP7366897B2/ja
Application filed by Iteos Therapeutics Sa filed Critical Iteos Therapeutics Sa
Priority to MX2020000960A priority patent/MX2020000960A/es
Priority to EP18750302.4A priority patent/EP3484925B1/fr
Priority to EP20173561.0A priority patent/EP3719040A1/fr
Priority to AU2018306463A priority patent/AU2018306463A1/en
Priority to US16/159,506 priority patent/US10329349B2/en
Publication of WO2019023504A1 publication Critical patent/WO2019023504A1/fr
Priority to US16/413,557 priority patent/US11439705B2/en
Priority to IL272227A priority patent/IL272227A/en
Priority to US17/872,494 priority patent/US20230190931A1/en
Priority to US17/946,158 priority patent/US20230181731A1/en
Priority to JP2023123773A priority patent/JP2023153911A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • Cancer immunotherapy relies on the modulation of the immune system to increase recognition and response against tumour cells. Such modulation can be achieved by multiple mechanisms including the activation of co-stimulatory molecules present on immune cells or through the inhibition of co- inhibitory receptors.
  • the activation of an immune response is a complex mechanism involving numerous cell populations like antigen-presenting cells important for the initiation of the antigen- specific response and effector cells responsible for tumour cell destruction.
  • the mechanisms modulating the activity of effector cells like cytotoxic T cells are numerous and represent target of choice in the context of cancer immunotherapy.
  • TIGIT T cell Immunoreceptor with Ig and ITIM domains
  • WUCAM WUCAM
  • VSIG9 Vstm3
  • TIGIT is transmembrane protein containing a known ITIM domain in its intracellular portion, a transmembrane domain and an immunoglobulin variable domain on the extracellular part of the receptor.
  • DNAM/CD226, a known co-stimulatory receptor also expressed on NK and T cells competes with TIGIT for CD155 and CD1 12 binding but with a lower affinity, which suggests a tight control of the activation of these effector cells to avoid uncontrolled cytotoxicity against normal cells expressing CD155 ligand.
  • TIGIT expression is increased on tumour infiltrating lymphocytes (TILs) and in disease settings such as HIV infection.
  • TIGIT expression marks exhausted T cells that have lower effector function as compared to TIGIT negative counterparts (Kurtulus et al. (2015) J. Clin . Invest. 276: 1 12; Chew et al. (2016) Plos Pathogens. 12).
  • Treg cells that express TIGIT show enhanced
  • antagonistic anti-TIGIT antibody may help to turn-on the immune system and better fight cancer cells. It has been suggested that antagonistic anti-TIGIT antibodies in monotherapy or in combination with a-PD1 antibody could achieve strong anti-tumour efficacy in preclinical models (Johnston et al. (2014) Cancer Cell 26: 1 ; WO2016/028656;
  • antagonistic antibodies specific for TIGIT that could inhibit TIGIT receptor activity represent an opportunity to decrease the immunosuppressive effect associated with tumour microenvironments and thereby increase antitumor immune response against tumour cells.
  • the present invention provides anti-TIGIT antibodies that can decrease the immunosuppressive effect of TIGIT-mediated signalling.
  • antibodies or antigen binding fragments of the invention can inhibit TIGIT-mediated immunosuppression through prevention of ligand binding on T cells (conventional ⁇ T cells and non-conventional ⁇ T cells) and NK cells and/or depletion of TIGIT positive Treg cells, and/or by inducing internalisation of the TIGIT receptor.
  • the present invention provides an isolated antibody or antigen binding fragment thereof which binds to human TIGIT and which comprises a heavy chain variable domain comprising a heavy chain CDR1 (HCDR1), a heavy chain CDR2 (HCDR2), and a heavy chain CDR3 (HCDR3) selected from the HCDR1 , HCDR2 and HCDR3 sequences shown in Figure 1 and which further comprises a light chain variable domain comprising a light chain CDR1 (LCDR1), a light chain CDR2 (LCDR2), and a light chain CDR3 (LCDR3) selected from the LCDR1 , LCDR2, and LCDR3 sequences shown in Figure 2.
  • HCDR1 heavy chain CDR1
  • HCDR2 heavy chain CDR2
  • HCDR3 heavy chain CDR3
  • the antibody or antigen binding fragment comprises a combination of HCDR1 , HCDR2, HCDR3, LCDR1 , LCDR2 and LCDR3, wherein the combination is selected from the group of combinations formed by the HCDRs from each antibody in Figure 1 taken with the LCDRs from the corresponding antibody in Figure 2.
  • an antibody or antigen binding fragment according the invention may comprise a heavy chain variable domain having an amino acid sequence selected from the group consisting of: SEQ ID Nos: 21 1 , 213, 215, 217, 219, 221 , 223, 225, 227, 229, 231 , 233, 235, 237, 239, 327, 329, and 331 and amino acid sequences exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto; and optionally comprise a light chain variable domain having an amino acid sequence selected from the group consisting of: the amino acid sequences of SEQ ID Nos: 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 328, 330, and 332and amino acid sequences exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto.
  • the antibody or antigen binding fragment comprises a combination of a heavy chain variable domain and a light chain variable domain, wherein the combination is selected from the group of combinations formed by the VH from each antibody in Figure 5, or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto, taken with the VL from the same antibody in Figure 5, or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto.
  • the most-preferred antibodies and antigen binding fragments provided herein are those based on the CDRs or complete variable domains of antibody 31282 provided herein.
  • these preferred anti-TIGIT antibodies and antigen binding fragments based on antibody 31282 have particularly surprising and advantageous properties. These properties include: a higher affinity for TIGIT expressed on CD8 T cells (from healthy donors or from cancer patients) compared to each previously described anti-TIGIT antibody tested; a better IC50 for competition with CD155/PVR compared to each previously described anti-TIGIT antibody tested; a better EC50 in T cell activation assays compared to each previously described anti-TIGIT antibody tested; and potently increasing activity in T cells from cancer patient peripheral blood, and importantly in tumour infiltrating lymphocytes.
  • antibodies and antigen binding fragments according to the invention preferentially deplete Treg cells. That is, TIGIT-expressing Treg cells exposed to the provided anti- TIGIT antibodies undergo lysis to a greater proportion compared to conventional CD4 and CD8 T cells. This is surprising because conventional CD4 and CD8 T cells also express TIGIT, but do not undergo cell lysis to the same extent when contacted with the antibodies. It is further surprisingly shown that antibodies and antigen binding fragments according to the invention, especially those based on antibody 31282 not only promote conventional T cell pro-inflammatory activity, but also increase activity of non-conventional ⁇ T cells.
  • an antibody or antigen binding fragment comprising HCDR1 , HCDR2, HCDR3, LCDR1 , LCDR2, and LCDR3 wherein:
  • HCDR1 comprises or consists of SEQ ID NO: 16 (YTFTSYYMH),
  • HCDR2 comprises or consists of SEQ ID NO: 17 (VIGPSGASTSYAQKFQG),
  • HCDR3 comprises or consists of SEQ ID NO: 18 (ARDHSDYWSGIMEV),
  • LCDR1 comprises or consists of SEQ ID NO: 61 (RASQS VRSSYLA) ,
  • LCDR2 comprises or consists of SEQ ID NO: 62 (GASSRAT), and
  • LCDR3 comprises or consists of SEQ ID NO: 63 (QQYFSPPWT).
  • the heavy chain variable domain comprises or consists of an amino acid sequence according to SEQ ID NO: 221 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto
  • the light chain variable domain comprises or consists of an amino acid sequence according to SEQ ID NO: 222 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto.
  • the anti-TIGIT antibody is antibody 31282 described herein.
  • the invention provides an isolated antibody or antigen binding fragment thereof, which cross-competes for binding to human TIGIT with an antibody according to the first aspect of the invention, for example an antibody exemplified herein.
  • the invention provides an isolated antibody or antigen binding fragment thereof, which binds to the same epitope as an antibody according to the first aspect of the invention, for example an antibody exemplified herein.
  • the invention provides an antibody or antigen binding fragment thereof which binds to an epitope of human TIGIT comprising TIGIT residues Q56, and 1109, optionally comprising residues Q56, N58 and 1109.
  • an antibody or antigen binding fragment thereof which binds to an epitope of human TIGIT comprising TIGIT residues Q56, N58, E60, I68, L73, H76, and 1109.
  • the antibody or antigen binding fragment thereof binds to an epitope of human TIGIT consisting of TIGIT residues Q56, N58, E60, 168, L73, H76, and 1109.
  • the invention provides an isolated antibody or antigen binding fragment thereof which binds to human TIGIT and which does not compete with CD155 for TIGIT binding.
  • the antibody or antigen binding fragment which binds to human TIGIT and which does not compete with CD155 for TIGIT binding comprises HCDR1 , HCDR2, HCDR3, LCDR1 , LCDR2, and LCDR3 wherein HCDR1 comprises or consists of SEQ ID NO: 280, HCDR2 comprises or consists of SEQ ID NO: 281 , HCDR3 comprises or consists of SEQ ID NO: 282, and LCDR1 comprises or consists of SEQ ID NO: 292, LCDR2 comprises or consists of SEQ ID NO: 293, and LCDR3 comprises or consists of SEQ ID NO: 294.
  • the heavy chain variable domain comprises or consists of the amino acid sequence shown as SEQ ID NO: 333 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto
  • the light chain variable domain comprises or consists of the amino acid sequence shown as SEQ ID NO: 334 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto.
  • the antibody which binds to human TIGIT and which does not compete with CD155 for TIGIT binding comprises a heavy chain variable domain and a light chain variable domain wherein HCDR1 comprises SEQ ID NO: 353, HCDR2 comprises SEQ ID NO: 354, HCDR3 comprises SEQ ID NO: 355, and LCDR1 comprises SEQ ID NO: 356, LCDR2 comprises SEQ ID NO: 357, and LCDR3 comprises SEQ ID NO: 358.
  • the heavy chain variable domain may comprise the amino acid sequence shown as SEQ ID NO: 367 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto
  • the light chain variable domain may comprise the amino acid sequence shown as SEQ ID NO: 368 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto.
  • the invention provides an isolated anti-TIGIT antibody or antigen binding fragment thereof which preferentially depletes TIGIT-expressing Treg cells, optionally wherein the antibody or antigen binding fragment is an antibody or antigen binding fragment according to the first aspect of the invention, for example an antibody exemplified herein..
  • the invention provides an affinity variant of an antibody according to other aspects of the invention, for example an antibody exemplified herein.
  • the invention provides an isolated polynucleotide or combination of isolated polynucleotides encoding an antibody or antigen binding fragment according to any other aspect of the invention, for example an antibody exemplified herein.
  • the invention provides an isolated polynucleotide encoding a VH and/or a VL domain of an anti-TIGIT antibody, wherein the polynucleotide comprises one or more sequences selected from the group consisting of SEQ ID Nos: 241 -270, 335-342 and 369-370.
  • the invention provides an expression vector comprising a polynucleotide or combination of polynucleotides according to the invention operably linked to regulatory sequences which permit expression of the antigen binding polypeptide in a host cell or cell-free expression system.
  • the invention provides a host cell or cell-free expression system containing an expression vector according to the invention.
  • the invention provides a method of producing a recombinant antibody or antigen binding fragment thereof which comprises culturing a host cell or cell free expression system according to the invention under conditions which permit expression of the antibody or antigen binding fragment and recovering the expressed antibody or antigen binding fragment.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising an antibody or antigen binding fragment according to the invention, for example an antibody exemplified herein, and at least one pharmaceutically acceptable carrier or excipient.
  • the invention provides an antibody or antigen-binding fragment according to the invention or pharmaceutical composition according to the invention for use in therapy.
  • the invention provides an antibody or antigen-binding fragment according to the invention (for example an antibody exemplified herein) or pharmaceutical composition according to the invention for use in a method of treating cancer.
  • an antibody or antigen-binding fragment according to the invention for example an antibody exemplified herein
  • pharmaceutical composition according to the invention for use in a method of treating cancer.
  • the invention provides an antibody or antigen-binding fragment according to the invention (for example an antibody exemplified herein) or pharmaceutical composition according to the invention for use in a method of treating viral infection, optionally CMV infection.
  • the invention provides a method of treating cancer in a subject comprising administering an effective amount of an antibody or antigen-binding fragment according to the invention (for example an antibody exemplified herein) or pharmaceutical composition according to the invention to the subject, thereby treating the cancer.
  • a method of treating viral infection in a subject comprising
  • the viral infection is CMV infection.
  • a method of promoting T cell activity comprising contacting a population of T cells with an antibody or antigen binding fragment according to the invention. In certain embodiments the method promotes ⁇ T cell activity. In certain embodiments the method promotes ⁇ T cell activity. In certain embodiments the method is performed in vitro. In certain embodiments the method is performed in vivo, for example in a human subject.
  • a method according to the invention or an antibody or antigen- binding fragment or pharmaceutical composition for use in a method according to the invention, wherein the method further comprises administration of one or more additional therapeutic agents.
  • the one or more additional agents are selected from: a
  • chemotherapeutic agent an anti-PD1 antibody, an anti-PD-L1 antibody, an anti-41 BB antibody, an anti-OX40 antibody, an anti-GITR antibody, and an anti-ICOS antibody.
  • a combination comprising an anti-TIGIT antibody or antigen binding fragment thereof and one or more of a chemotherapeutic agent, an anti-PD1 antibody, an anti-PD-L1 antibody, an anti-41 BB antibody, an anti-OX40 antibody, an anti-GITR antibody, and an anti-ICOS antibody.
  • a combination according to the invention for use in therapy.
  • a combination according to the invention for use in a method of treating cancer or for use in a method of treating viral infection.
  • a combination according to the invention for use in a method according to the invention for use in a method according to the invention.
  • the anti-TIGIT antibody or antigen binding fragment thereof is an antibody of the invention or an antigen binding fragment thereof.
  • any subject to be treated is a human subject.
  • cells e.g. T cells
  • antibodies according to the invention are human cells (e.g. human T cells).
  • Figure 7 Graph showing the results of a competition assay between hCD155 and anti-TIGIT antibody for binding to Jurkat-hTIGIT
  • Figure 9 Graph showing the results of a binding assay of anti-TIGIT antibody on Jurkat-hTIGIT Figure 10
  • a and B Graphs showing the results of a binding assay of anti-TIGIT antibody on primary CD8 + T cells from human healthy PBMCs.
  • C Graph showing the results of a binding assay of anti-TIGIT antibody on primary memory CD8 + T cells and Treg from human healthy PBMCs
  • Figure 14 Histogram plots showing the effect of anti-TIGIT antibody to increase IFNg secretion in a functional assay on human primary CD8 + TILs from an ovarian ascites activated with CHO-TCR-CD155 cells
  • Figure 15 (A) Graph showing the results of a competition assay between mouse CD155 and anti-TIGIT antibody for binding to Jurkat-mTIGIT. (B) Graph showing the effect of anti-TIGIT antibody to increase IFNg secretion in a functional assay on mouse OT-1 T cells. (C) Graph showing the effect of anti-TIGIT antibody to increase cytotoxicity in a functional assay on mouse OT-1 T cells.
  • Figure 16 (A) Graph showing the anti-tumor efficacy of anti-TIGIT antibody in monotherapy in a CT26 tumor model. (B and C) Graphs showing the anti-tumor efficacy of anti-TIGIT antibody in combination with anti-PD1 in a CT26 tumor model.
  • Figure 17 (A) Graph showing the isotype dependant anti-tumor efficacy of anti-TIGIT antibody in monotherapy in a CT26 tumor model. (B) Graph showing the isotype dependant antitumor efficacy of anti-TIGIT antibody in combination with anti-PD1 in a CT26 tumor model.
  • CD8 + T cell within total CD45 + population in CT26 tumor treated with anti-TIGIT antibody in monotherapy or combination with anti-PD1 .
  • C and I Graphs showing the modulation of CD8VTreg T cell ratio in CT26 tumor treated with anti-TIGIT antibody in monotherapy or combination with anti-PD1 .
  • D and J Graph showing the modulation of IFNg secreting CD4 + T cells in CT26 tumor treated with anti-TIGIT antibody in monotherapy or combination with anti-PD1 .
  • E Graph showing the modulation of IFNg secreting CD8 + T cells in CT26 tumor treated with anti-TIGIT antibody.
  • TIGIT antibody in combination with anti-PD1 antibody.
  • FIG. 19 (A) Volcano plot showing the effect of anti-TIGIT antibody treatment to modulate gene expression in CT26 tumor and measured by NanoString analysis. (B) Box plot showing the modulation of cytotoxic score in CT26 tumor treated with anti-TIGIT antibody in monotherapy or combination with anti-PD1 . (C) Box plot showing the modulation of CD8 + T cell score in CT26 tumor treated with anti-TIGIT antibody in monotherapy or combination with anti-PD1
  • Figure 20 (A) Histogram plots showing the proportion of TIGIT + CD4 + , CD8 + T cell and Treg populations in PBMC from human healthy volunteers. (B) Graph showing the in vitro cytotoxicity effect of anti-TIGIT antibody on conventional CD4 + , CD8 + T cell and Treg populations in PBMC from human healthy volunteers.
  • CD4 + , CD8 + T cell and Treg populations in CT26 tumour CD4 + , CD8 + T cell and Treg populations in CT26 tumour.
  • Figure 22 (A) Graph showing the results of a binding assay of anti-TIGIT antibody clones on
  • Figure 23 Graph showing the results of a competition assay between human CD155 and anti- TIGIT antibody clones for binding to Jurkat-hTIGIT
  • Figure 24 Graph showing the functional characterization of antagonist a-TIGIT clones.
  • D Graph showing the effect of anti-TIGIT antibody clone 31282 in functional assay measuring intracellular cytokine staining in cancer patient TILs or PBMCs.
  • FIG. 26 Graph showing the characterization of TIGIT expression on immune populations from cancer patients.
  • A Frequency of TIGIT expression on immune populations from cancer patient PBMC and TILs.
  • B Absolute quantification of TIGIT expression on immune populations from cancer patient PBMC and TILs.
  • Figure 27 (A) Structure of the Fab:TIGIT complex shown as ribbon diagram; (B) Full binding interface between clone 31282 and TIGIT; (C) Binding interface between clone 31282 and TIGIT showing contacted residues.
  • Figure 29 Measure of plasma concentration of anti-TIGIT clone 31282 after i.v. injection of a single dose at 0.1 mg/kg (top row), 1 mg/kg (middle row) or 10 mg/kg (bottom row) in Cynomolgus monkey.
  • CD4 + T cell populations from patient with Sezary Syndrome.
  • A Gating strategy to separate malignant and normal CD4 + T cells.
  • B MFI for TIGIT staining on the 2 distinct populations.
  • FIG. 31 Graph showing the characterization of TIGIT expression on malignant and normal B cell populations from patient with CLL.
  • A Gating strategy to separate malignant and normal B cells.
  • B MFI for TIGIT staining on the 2 distinct populations.
  • Figure 32 (A-C) Graph showing the tumor growth curves in mice inoculated with EL4-mTIGIT tumors.
  • A Median tumor growth curves.
  • B Individual tumor growth curves in mice treated with hlgG1 isotype control antibody.
  • C Individual tumor growth curves in mice treated with mouse surrogate antagonist a-TIGIT antibody (hlgG1).
  • D-F Graph showing the tumor growth curves in mice inoculated with EL4-GFP tumors.
  • D Median tumor growth curves.
  • E Individual tumor growth curves in mice treated with hlgG1 isotype control antibody.
  • F Individual tumor growth curves in mice treated with surrogate antagonist a-TIGIT (hlgG1).
  • Figure 33 (A-D) Graphs showing the tumor growth curves in mice inoculated with CT26 tumors.
  • A Median and individual tumor growth curves for mice treated with anti-TIGIT and anti-4-1 BB antibodies.
  • B Median and individual tumor growth curves for mice treated with anti-TIGIT and anti-OX-40 antibodies.
  • C Median and individual tumor growth curves for mice treated with anti-TIGIT and anti-GITR antibodies.
  • D Median and individual tumor growth curves for mice treated with anti-TIGIT and anti-ICOS antibodies.
  • immunoglobulin includes a polypeptide having a combination of two heavy and two light chains whether or not it possesses any relevant specific immunoreactivity.
  • Antibodies refers to such assemblies which have significant known specific immunoreactive activity to an antigen of interest (e.g. TIGIT).
  • TIGIT antibodies or “anti-TIGIT antibodies” are used herein to refer to antibodies which exhibit immunological specificity for TIGIT protein.
  • immunoglobulins comprise light and heavy chains, with or without an interchain covalent linkage between them.
  • Basic immunoglobulin structures in vertebrate systems are relatively well understood.
  • the generic term "immunoglobulin" comprises five distinct classes of antibody that can be
  • immunoglobulin molecules comprise two identical light polypeptide chains of molecular weight approximately 23,000 Daltons, and two identical heavy chains of molecular weight 53,000-70,000. The four chains are joined by disulfide bonds in a "Y" configuration wherein the light chains bracket the heavy chains starting at the mouth of the "Y” and continuing through the variable region.
  • the light chains of an antibody are classified as either kappa or lambda ( ⁇ , ⁇ ). Each heavy chain class may be bound with either a kappa or lambda light chain.
  • the light and heavy chains are covalently bonded to each other, and the "tail" portions of the two heavy chains are bonded to each other by covalent disulfide linkages or non-covalent linkages when the immunoglobulins are generated by B cells or genetically engineered host cells.
  • the amino acid sequences run from an N-terminus at the forked ends of the Y configuration to the C-terminus at the bottom of each chain.
  • heavy chains are classified as gamma, mu, alpha, delta, or epsilon, ( ⁇ , ⁇ , ⁇ , ⁇ , ⁇ ) with some subclasses among them (e.g., ⁇ 1 - ⁇ 4). It is the nature of this chain that determines the "class" of the antibody as IgG, IgM, IgA, IgD or IgE, respectively.
  • the immunoglobulin subclasses e.g., lgG1 , lgG2, lgG3, lgG4, lgA1 , etc. are well characterized and are known to confer functional specialization. Modified versions of each of these classes and isotypes are readily discernible to the skilled artisan in view of the instant disclosure and , accordingly, are within the scope of the instant invention .
  • variable region of an antibody allows the antibody to selectively recognize and specifically bind epitopes on antigens. That is, the VL domain and VH domain of an antibody combine to form the variable region that defines a three dimensional antigen binding site.
  • This quaternary antibody structure forms the antigen binding site present at the end of each arm of the Y. More specifically, the antigen binding site is defined by three complementary determining regions (CDRs) on each of the VH and VL chains.
  • CDRs complementary determining regions
  • TIGIT protein or “TIGIT antigen” or “TIGIT” are used interchangeably and refer to the human T-cell immunoreceptor (GenBank accession number: NM_173799) that binds the poliovirus receptor (PVR - also known as CD155).
  • TIGIT is also known as VSIG9, VSTM3, or WUCAM.
  • Reference to TIGIT includes the native human TIGIT protein naturally expressed in the human host and/or on the surface of human cultured cell lines, as well as recombinant forms and fragments thereof and also naturally occurring mutant forms.
  • binding site comprises a region of a polypeptide which is responsible for selectively binding to a target antigen of interest (e.g. TIGIT). Binding domains comprise at least one binding site. Exemplary binding domains include an antibody variable domain .
  • the antibody molecules of the invention may comprise a single binding site or multiple (e.g ., two, three or four) binding sites.
  • the term "derived from” a designated protein refers to the origin of the polypeptide.
  • the polypeptide or amino acid sequence which is derived from a particular starting polypeptide is a CDR sequence or sequence related thereto.
  • the amino acid sequence which is derived from a particular starting polypeptide is not contiguous. For example, in one embodiment, one, two, three, four, five, or six CDRs are derived from a starting antibody.
  • the polypeptide or amino acid sequence which is derived from a particular starting polypeptide or amino acid sequence has an amino acid sequence that is essentially identical to that of the starting sequence, or a portion thereof wherein the portion consists of at least 3-5 amino acids, at least 5-10 amino acids, at least 10-20 amino acids, at least 20-30 amino acids, or at least 30-50 amino acids, or which is otherwise identifiable to one of ordinary skill in the art as having its origin in the starting sequence.
  • the one or more CDR sequences derived from the starting antibody are altered to produce variant CDR sequences, e.g. affinity variants, wherein the variant CDR sequences maintain TIGIT binding activity.
  • a "conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain .
  • Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g ., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine,
  • a nonessential amino acid residue in an immunoglobulin polypeptide may be replaced with another amino acid residue from the same side chain family.
  • a string of amino acids can be replaced with a structurally similar string that differs in order and/or composition of side chain family members.
  • heavy chain portion includes amino acid sequences derived from the constant domains of an immunoglobulin heavy chain.
  • a polypeptide comprising a heavy chain portion comprises at least one of: a CH1 domain, a hinge (e.g., upper, middle, and/or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment thereof.
  • an antibody or antigen binding fragment of the invention may comprise the Fc portion of an immunoglobulin heavy chain.
  • an antibody or antigen binding fragment of the invention may lack at least a portion of a constant domain (e.g., all or part of a CH2 domain).
  • at least one, and preferably all, of the constant domains are derived from a human immunoglobulin heavy chain.
  • the heavy chain portion comprises a fully human hinge domain.
  • the heavy chain portion comprises a fully human Fc portion (e.g., hinge, CH2 and CH3 domain sequences from a human immunoglobulin).
  • the constituent constant domains of the heavy chain portion are from different immunoglobulin molecules.
  • a heavy chain portion of a polypeptide may comprise a CH2 domain derived from an lgG1 molecule and a hinge region derived from an lgG3 or lgG4 molecule.
  • the constant domains are chimeric domains comprising portions of different immunoglobulin molecules.
  • a hinge may comprise a first portion from an lgG1 molecule and a second portion from an lgG3 or lgG4 molecule.
  • the constant domains of the heavy chain portion may be modified such that they vary in amino acid sequence from the naturally occurring (wild-type) immunoglobulin molecule. That is, the polypeptides of the invention disclosed herein may comprise alterations or modifications to one or more of the heavy chain constant domains (CH1 , hinge, CH2 or CH3) and/or to the light chain constant region domain (CL). Exemplary modifications include additions, deletions or substitutions of one or more amino acids in one or more domains.
  • variable region and “variable domain” are used interchangeably and are intended to have equivalent meaning.
  • variable refers to the fact that certain portions of the variable domains VH and VL differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its target antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called “hypervariable loops" in each of the VL domain and the VH domain which form part of the antigen binding site.
  • the first, second and third hypervariable loops of the V_ambda light chain domain are referred to herein as L1 ( ⁇ ), ⁇ _2( ⁇ ) and ⁇ _3( ⁇ ) and may be defined as comprising residues 24-33 ( ⁇ _1 ( ⁇ ), consisting of 9, 10 or 1 1 amino acid residues), 49-53 ( ⁇ _2( ⁇ ), consisting of 3 residues) and 90- 96 (L3(A), consisting of 5 residues) in the VL domain (Morea et al., Methods 20, 267-279, 2000).
  • the first, second and third hypervariable loops of the VKappa light chain domain are referred to herein as L1 (K), L2(K) and L3(K) and may be defined as comprising residues 25-33 (L1 (K), consisting of 6, 7, 8, 1 1 , 12 or 13 residues), 49-53 (L2(K), consisting of 3 residues) and 90-97 (L3(K), consisting of 6 residues) in the VL domain (Morea et al., Methods 20, 267-279, 2000).
  • the first, second and third hypervariable loops of the VH domain are referred to herein as H1 , H2 and H3 and may be defined as comprising residues 25-33 (H1 , consisting of 7, 8 or 9 residues), 52-56 (H2, consisting of 3 or 4 residues) and 91 -105 (H3, highly variable in length) in the VH domain (Morea et al., Methods 20, 267- 279, 2000).
  • L1 , L2 and L3 respectively refer to the first, second and third hypervariable loops of a VL domain, and encompass hypervariable loops obtained from both VKappa and VLambda isotypes.
  • H1 , H2 and H3 respectively refer to the first, second and third hypervariable loops of the VH domain, and encompass hypervariable loops obtained from any of the known heavy chain isotypes, including ⁇ , ⁇ , ⁇ , a or ⁇ .
  • hypervariable loops L1 , L2, L3, H1 , H2 and H3 may each comprise part of a "complementarity determining region" or "CDR”, as defined below.
  • CDR complementarity determining region
  • complementarity determining region are not strictly synonymous, since the hypervariable loops (HVs) are defined on the basis of structure, whereas complementarity determining regions (CDRs) are defined based on sequence variability (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991) and the limits of the HVs and the CDRs may be different in some VH and VL domains.
  • the CDRs of the VL and VH domains can typically be defined as comprising the following amino acids: residues 24-34 (LCDR1), 50-56 (LCDR2) and 89-97 (LCDR3) in the light chain variable domain, and residues 31 -35 or 31 -35b (HCDR1), 50-65 (HCDR2) and 95-102 (HCDR3) in the heavy chain variable domain; (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991).
  • the HVs may be comprised within the corresponding CDRs and references herein to the "hypervariable loops" of VH and VL domains should be interpreted as also encompassing the corresponding CDRs, and vice versa, unless otherwise indicated.
  • variable domains The more highly conserved portions of variable domains are called the framework region (FR), as defined below.
  • the variable domains of native heavy and light chains each comprise four FRs (FR1 , FR2, FR3 and FR4, respectively), largely adopting a ⁇ -sheet configuration, connected by the three hypervariable loops.
  • the hypervariable loops in each chain are held together in close proximity by the FRs and, with the hypervariable loops from the other chain, contribute to the formation of the antigen-binding site of antibodies.
  • Structural analysis of antibodies revealed the relationship between the sequence and the shape of the binding site formed by the complementarity determining regions (Chothia et al., J. Mol. Biol.
  • CDR complementarity determining region
  • CDR is a CDR as defined by Kabat based on sequence comparisons.
  • Residue numbering follows the nomenclature of Kabat et al., supra
  • variable region includes the amino acid residues that are part of the variable region, but are not part of the CDRs (e.g., using the Kabat definition of CDRs). Therefore, a variable region framework is between about 100-120 amino acids in length but includes only those amino acids outside of the CDRs.
  • the framework regions for the light chain are similarly separated by each of the light claim variable region CDRs.
  • the framework region boundaries are separated by the respective CDR termini as described above. In preferred embodiments the CDRs are as defined by Kabat.
  • the six CDRs present on each monomeric antibody are short, noncontiguous sequences of amino acids that are specifically positioned to form the antigen binding site as the antibody assumes its three dimensional configuration in an aqueous environment.
  • the remainder of the heavy and light variable domains show less inter-molecular variability in amino acid sequence and are termed the framework regions.
  • the framework regions largely adopt a ⁇ -sheet conformation and the CDRs form loops which connect, and in some cases form part of, the ⁇ -sheet structure. Thus, these framework regions act to form a scaffold that provides for positioning the six CDRs in correct orientation by inter-chain, non-covalent interactions.
  • the antigen binding site formed by the positioned CDRs defines a surface complementary to the epitope on the immunoreactive antigen. This complementary surface promotes the non-covalent binding of the antibody to the immunoreactive antigen epitope.
  • the position of CDRs can be readily identified by one of ordinary skill in the art.
  • fragment refers to a part or portion of an antibody or antibody chain comprising fewer amino acid residues than an intact or complete antibody or antibody chain.
  • antigen-binding fragment refers to a polypeptide fragment of an immunoglobulin or antibody that binds antigen or competes with intact antibody (i.e., with the intact antibody from which they were derived) for antigen binding (i.e., specific binding to TIGIT).
  • fragment of an antibody molecule includes antigen-binding fragments of antibodies, for example, an antibody light chain variable domain (VL), an antibody heavy chain variable domain (VH), a single chain antibody (scFv), a F(ab')2 fragment, a Fab fragment, an Fd fragment, an Fv fragment, and a single domain antibody fragment (DAb). Fragments can be obtained, e.g., via chemical or enzymatic treatment of an intact or complete antibody or antibody chain or by recombinant means.
  • VL antibody light chain variable domain
  • VH antibody heavy chain variable domain
  • scFv single chain antibody
  • F(ab')2 fragment fragment
  • Fab fragment fragment
  • Fd fragment fragment
  • Fv fragment single domain antibody fragment
  • DAb single domain antibody fragment
  • valency refers to the number of potential target binding sites in a polypeptide.
  • Each target binding site specifically binds one target molecule or specific site on a target molecule.
  • each target binding site may specifically bind the same or different molecules (e.g., may bind to different ligands or different antigens, or different epitopes on the same antigen).
  • the subject binding molecules have at least one binding site specific for TIGIT.
  • the term "specificity" refers to the ability to bind (e.g., immunoreact with) a given target, e.g., TIGIT.
  • a polypeptide may be monospecific and contain one or more binding sites which specifically bind a target or a polypeptide may be multispecific and contain two or more binding sites which specifically bind the same or different targets.
  • an antibody of the invention is specific for more than one target.
  • a multispecific binding molecule of the invention binds TIGIT and a second target molecule.
  • the second target molecule is a molecule other than TIGIT.
  • polypeptides which comprise an amino acid sequence that is not naturally occurring.
  • non-naturally occurring polypeptides which are modified forms of naturally occurring polypeptides (e.g., comprising a mutation such as an addition, substitution or deletion) or which comprise a first amino acid sequence (which may or may not be naturally occurring) that is linked in a linear sequence of amino acids to a second amino acid sequence (which may or may not be naturally occurring) to which it is not naturally linked in nature.
  • the term "engineered” includes manipulation of nucleic acid or polypeptide molecules by synthetic means (e.g. by recombinant techniques, in vitro peptide synthesis, by enzymatic or chemical coupling of peptides or some combination of these techniques).
  • the antibodies of the invention have been engineered to improve one or more properties, such as antigen binding, stability/half-life or effector function.
  • modified antibody includes synthetic forms of antibodies which are altered such that they are not naturally occurring, e.g., antibodies that comprise at least two heavy chain portions but not two complete heavy chains (such as, domain deleted antibodies or minibodies); multispecific forms of antibodies (e.g., bispecific, trispecific, etc.) altered to bind to two or more different antigens or to different epitopes on a single antigen; heavy chain molecules joined to scFv molecules and the like. ScFv molecules are known in the art and are described, e.g., in US patent 5,892,019.
  • modified antibody includes multivalent forms of antibodies (e.g., trivalent, tetravalent, etc., antibodies that bind to three or more copies of the same antigen).
  • a modified antibody of the invention is a fusion protein comprising at least one heavy chain portion lacking a CH2 domain and comprising a binding domain of a polypeptide comprising the binding portion of one member of a receptor ligand pair.
  • modified antibody may also be used herein to refer to amino acid sequence variants of a TIGIT antibody of the invention. It will be understood by one of ordinary skill in the art that a TIGIT antibody of the invention may be modified to produce a variant TIGIT antibody which varies in amino acid sequence in comparison to the TIGIT antibody from which it was derived. For example, nucleotide or amino acid substitutions leading to conservative substitutions or changes at "nonessential" amino acid residues may be made (e.g., in CDR and/or framework residues). Amino acid substitutions can include replacement of one or more amino acids with a naturally occurring or non- natural amino acid.
  • Antibody fragments comprise a portion of a full length antibody, generally the antigen binding or variable domain thereof.
  • antigen binding antibody fragments include Fab, Fab', F(ab')2, bi-specific Fab's, and Fv fragments, diabodies, linear antibodies, single-chain antibody molecules, a single chain variable fragment (scFv) and multispecific antibodies formed from antibody fragments (see Holliger and Hudson, Nature Biotechnol. 23:1 126-1 136, 2005, the contents of which are incorporated herein by reference).
  • affinity variant refers to a variant antibody which exhibits one or more changes in amino acid sequence compared to a reference TIGIT antibody of the invention, wherein the affinity variant exhibits an altered affinity for TIGIT in comparison to the reference antibody.
  • the affinity variant will exhibit improved affinity for TIGIT, as compared to the reference TIGIT antibody.
  • the improvement may be apparent as a lower KD for TIGIT, or a slower off-rate for TIGIT.
  • Affinity variants typically exhibit one or more changes in amino acid sequence in the CDRs, as compared to the reference TIGIT antibody. Such substitutions may result in replacement of the original amino acid present at a given position in the CDRs with a different amino acid residue, which may be a naturally occurring amino acid residue or a non-naturally occurring amino acid residue. The amino acid substitutions may be conservative or non-conservative.
  • affinity or “binding affinity” should be understood based on the usual meaning in the art in the context of antibody binding, and reflects the strength and/or stability of binding between an antigen and a binding site on an antibody or antigen binding fragment thereof.
  • the anti-TIGIT antibodies provided herein are characterised by high affinity binding to human TIGIT. Binding affinity for TIGIT may be assessed using standard techniques known to persons of skill in the art.
  • Binding affinity may also be expressed as the dissociation constant for a particular antibody, or the KD. The lesser the KD value, the stronger the binding interaction between an antibody and its target antigen.
  • binding affinity of a Fab clone comprising a defined VH/VL pairing may be assessed by using methods known in the art, for example by the ForteBioTM system, by MSD- solution equilibrium titration (SET), or by surface plasmon resonance, e.g. using the BiacoreTM system as described in the accompanying examples.
  • Fab fragments of the antibodies according to the invention typically exhibit a KD for TIGIT measured by ForteBioTM in the range of from 1x10 0 to 5x 10 " 8 M, optionally 7 x10 0 to 4 x 10 8 M.
  • a KD within this range may be taken as an indication that the Fab, and a corresponding bivalent mAb, exhibit high affinity binding to hTIGIT.
  • Bivalent mAbs comprising two Fabs that (individually) exhibit KD for hTIGIT within the stated ranges are also taken to exhibit high affinity binding to hTIGIT.
  • a MSD KD in the range of from 1 x 10 ⁇ 11 to 5 x 10 ⁇ 9 , optionally 2 x 10 "11 to 1 x 10 ⁇ 9 may be taken as an indication of high affinity binding to hTIGIT.
  • Fab fragments of the antibodies according to the invention typically exhibit a KD for TIGIT measured by BiacoreTM in the range of from 1x10 0 M to 1x 10 9 M, optionally from 1 x10 " 0 to 7x10 10 , optionally 2 ⁇ 10 0 to 7 ⁇ 10 0 M.
  • a KD within this range may be taken as an indication that the Fab, and a corresponding bivalent mAb, exhibit high affinity binding to hTIGIT.
  • Binding affinity to human TIGIT can also be assessed using a cell-based system as described in the accompanying examples, in which mAbs are tested for binding to mammalian cells (cell lines or ex vivo cells that express TIGIT), for example using ELISA or flow cytometry.
  • High affinity for TIGIT may be indicated, for example, by an EC50 of no more than 0.5 nM by flow cytometric (e.g. FACS) analysis such as that described in Example 10.
  • flow cytometric e.g. FACS
  • antibodies of the invention exhibit a cell binding EC50 of no more than 0.5 nM, optionally no more than 0.2 nM.
  • Cell-based determination of affinity expressed as EC50 is preferably determined using Jurkat cells expressing hTIGIT or primary CD8 T cells from human peripheral blood mononuclear cells (PBMCs).
  • Treg cells refer to regulatory CD4+ T cells - that is, T cells that decrease the effector function(s) of conventional T cells (CD8 or CD4 T cells). Tregs can be identified according to methods known in the art, for example using flow cytometry to identify CD4 cells expressing high levels of CD25 and low levels or absence of CD127.
  • the invention relates, at least in part, to antibodies, and antigen binding fragments thereof, that bind to TIGIT.
  • TIGIT antibodies, and antigen binding fragments thereof, that bind to TIGIT.
  • the properties and characteristics of the TIGIT antibodies, and antibody fragments, according to the invention will now be described in further detail.
  • the present invention provides an isolated antibody or antigen binding fragment thereof which binds to human TIGIT and which comprises a heavy chain variable domain comprising a heavy chain CDR1 (HCDR1), a heavy chain CDR2 (HCDR2), and a heavy chain CDR3 (HCDR3) selected from the HCDR1 , HCDR2 and HCDR3 sequences shown in Figure 1 and which further comprises a light chain variable domain comprising a light chain CDR1 (LCDR1), a light chain CDR2 (LCDR2), and a light chain CDR3 (LCDR3) selected from the LCDR1 , LCDR2, and LCDR3 sequences shown in Figure 2.
  • HCDR1 heavy chain CDR1
  • HCDR2 heavy chain CDR2
  • HCDR3 heavy chain CDR3
  • the invention provides an isolated antibody or antigen binding fragment thereof which binds to human TIGIT and which comprises a heavy chain variable domain comprising a heavy chain CDR1 (HCDR1), a heavy chain CDR2 (HCDR2), and a heavy chain CDR3 (HCDR3), wherein: (i) HCDR1 is selected from the group consisting of SEQ ID Nos: 1 , 4, 7, 10, 13, 16, 19, 22,
  • HCDR2 is selected from the group consisting of SEQ ID Nos: 2, 5, 8, 1 1 , 14, 17, 20, 23,
  • HCDR3 is selected from the group consisting of SEQ ID Nos: 3, 6, 9, 12, 15, 18, 21 , 24, 27, 30, 33, 36, 39, 42, 45, 273, 276, and 279; and which further comprises a light chain variable domain comprising a light chain CDR1 (LCDR1), a light chain CDR2 (LCDR2), and a light chain CDR3 (LCDR3), wherein
  • LCDR1 is selected from the group consisting of SEQ ID Nos: 46, 49, 52, 55, 58, 61 , 64,
  • LCDR2 is selected from the group consisting of SEQ ID Nos: 47, 50, 53, 56, 59, 62, 65,
  • LCDR3 is selected from the group consisting of SEQ ID Nos: 48, 51 , 54, 57, 60, 63, 66,
  • Any given anti-TIGIT antibody or antigen binding fragment thereof comprising a VH domain paired with a VL domain to form a binding site for antigen will comprise a combination of 6 CDRs: variable heavy chain CDR3 (HCDR3), variable heavy chain CDR2 (HCDR2), variable heavy chain CDR1 (HCDR1), variable light chain CDR3 (LCDR3), variable light chain CDR2 (LCDR2) and variable light chain CDR1 (LCDR1).
  • the antibody or antigen binding fragment comprises a combination of HCDR1 , HCDR2, HCDR3, LCDR1 , LCDR2 and LCDR3, wherein the combination is selected from the group of combinations formed by the HCDRs from each antibody in Figure 1 taken with the LCDRs from the corresponding antibody in Figure 2.
  • the antibody or antigen binding fragment comprises a combination of HCDR1 , HCDR2, HCDR3, LCDR1 , LCDR2 and LCDR3, wherein the combination is selected from the group consisting of: (i) HCDR1 comprising SEQ ID NO:1 , HCDR2 comprising SEQ ID NO:2, HCDR3 comprising
  • LCDR1 comprising SEQ ID NO:46
  • LCDR2 comprising SEQ ID NO:47
  • LCDR3 comprising SEQ ID NO:48;
  • HCDR1 comprising SEQ ID NO:4, HCDR2 comprising SEQ ID NO:5, HCDR3 comprising SEQ ID NO:6, LCDR1 comprising SEQ ID NO:49, LCDR2 comprising SEQ ID NO:50, and LCDR3 comprising SEQ ID NO:51 ;
  • HCDR1 comprising SEQ ID NO:7
  • HCDR2 comprising SEQ ID NO:8
  • HCDR3 comprising SEQ ID NO:9
  • LCDR1 comprising SEQ ID NO:52
  • LCDR2 comprising SEQ ID NO:53
  • LCDR3 comprising SEQ ID NO:54;
  • HCDR1 comprising SEQ ID NO:10, HCDR2 comprising SEQ ID NO:1 1 , HCDR3 comprising SEQ ID NO:12, LCDR1 comprising SEQ ID NO:55, LCDR2 comprising SEQ ID NO:56, and LCDR3 comprising SEQ ID NO:57;
  • HCDR1 comprising SEQ ID NO:13, HCDR2 comprising SEQ ID NO:14, HCDR3 comprising SEQ ID NO:15, LCDR1 comprising SEQ ID NO:58, LCDR2 comprising SEQ ID NO:59, and LCDR3 comprising SEQ ID NO:60;
  • HCDR1 comprising SEQ ID NO:16, HCDR2 comprising SEQ ID NO:17, HCDR3 comprising SEQ ID NO:18, LCDR1 comprising SEQ ID NO:61 , LCDR2 comprising SEQ ID NO:62, and LCDR3 comprising SEQ ID NO:63;
  • HCDR1 comprising SEQ ID NO:19, HCDR2 comprising SEQ ID NO:20, HCDR3 comprising SEQ ID NO:21 , LCDR1 comprising SEQ ID NO:64, LCDR2 comprising SEQ ID NO:65, and LCDR3 comprising SEQ ID NO:66;
  • HCDR1 comprising SEQ ID NO:22, HCDR2 comprising SEQ ID NO:23, HCDR3 comprising SEQ ID NO:24, LCDR1 comprising SEQ ID NO:67, LCDR2 comprising SEQ ID NO:68, and LCDR3 comprising SEQ ID NO:69;
  • HCDR1 comprising SEQ ID NO:25, HCDR2 comprising SEQ ID NO:26, HCDR3 comprising SEQ ID NO:27, LCDR1 comprising SEQ ID NO:70, LCDR2 comprising SEQ ID NO:71 , and LCDR3 comprising SEQ ID NO:72;
  • HCDR1 comprising SEQ ID NO:28, HCDR2 comprising SEQ ID NO:29, HCDR3 comprising SEQ ID NO:30, LCDR1 comprising SEQ ID NO:73, LCDR2 comprising SEQ ID NO:74, and LCDR3 comprising SEQ ID NO:75;
  • HCDR1 comprising SEQ ID NO:31 , HCDR2 comprising SEQ ID NO:32, HCDR3 comprising SEQ ID NO:33, LCDR1 comprising SEQ ID NO:76, LCDR2 comprising SEQ ID NO:77, and LCDR3 comprising SEQ ID NO:78;
  • HCDR1 comprising SEQ ID NO:34, HCDR2 comprising SEQ ID NO:35, HCDR3 comprising SEQ ID NO:36, LCDR1 comprising SEQ ID NO:79, LCDR2 comprising SEQ ID NO:80, and LCDR3 comprising SEQ ID NO:81 ;
  • HCDR1 comprising SEQ ID NO:37, HCDR2 comprising SEQ ID NO:38, HCDR3 comprising SEQ ID NO:39, LCDR1 comprising SEQ ID NO:82, LCDR2 comprising SEQ ID NO:83, and LCDR3 comprising SEQ ID NO:84;
  • HCDR1 comprising SEQ ID NO:40, HCDR2 comprising SEQ ID NO:41 , HCDR3 comprising SEQ ID NO:42, LCDR1 comprising SEQ ID NO:85, LCDR2 comprising SEQ ID NO:86, and LCDR3 comprising SEQ ID NO:87;
  • HCDR1 comprising SEQ ID NO:43, HCDR2 comprising SEQ ID NO:44, HCDR3 comprising SEQ ID NO:45, LCDR1 comprising SEQ ID NO:88, LCDR2 comprising SEQ ID NO:89, and LCDR3 comprising SEQ ID NO:90;
  • HCDR1 comprising SEQ ID NO:271 , HCDR2 comprising SEQ ID NO:272, HCDR3 comprising SEQ ID NO:273, LCDR1 comprising SEQ ID NO:283, LCDR2 comprising SEQ ID NO:284, and LCDR3 comprising SEQ ID NO:285;
  • HCDR1 comprising SEQ ID NO:274, HCDR2 comprising SEQ ID NO:275, HCDR3 comprising SEQ ID NO:276, LCDR1 comprising SEQ ID NO:286, LCDR2 comprising SEQ ID NO:287, and LCDR3 comprising SEQ ID NO:288;
  • HCDR1 comprising SEQ ID NO:277, HCDR2 comprising SEQ ID NO:278, HCDR3 comprising SEQ ID NO:279, LCDR1 comprising SEQ ID NO:289, LCDR2 comprising SEQ ID NO:290, and LCDR3 comprising SEQ ID NO:291 .
  • the antibody or antigen binding fragment comprises a heavy chain variable domain having an amino acid sequence selected from the group consisting of: SEQ ID Nos: 21 1 , 213, 215, 217, 219, 221 , 223, 225, 227, 229, 231 , 233, 235, 237, 239, 327, 329, and 331 and amino acid sequences exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto; and optionally comprising a light chain variable domain having an amino acid sequence selected from the group consisting of: the amino acid sequences of SEQ ID Nos: 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 328, 330, and 332 and amino acid sequences exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto.
  • VH domains and VL domains selected from the VH and VL domain sequence groups listed above are permissible, and within the scope of the invention, certain combinations VH and VL are particularly preferred; these being the "native" combinations within a single mAb exhibiting high affinity binding to human TIGIT.
  • the antibody or antigen binding fragment comprises a combination of a heavy chain variable domain and a light chain variable domain, wherein the combination is selected from the group of combinations formed by the VH from each antibody in Figure 5, or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto, taken with the VL from the same antibody in Figure 5, or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto.
  • the antibody or antigen binding fragment comprises a combination of a heavy chain variable domain and a light chain variable domain, wherein the combination is selected from the group consisting of:
  • a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:223 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:224;
  • a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:225 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:226;
  • a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:327 or an amino acid sequence at least 90% identical thereto and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:328 or an amino acid sequence at least 90% identical thereto;
  • a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:329 or an amino acid sequence at least 90% identical thereto and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:330 or an amino acid sequence at least 90% identical thereto; and (xviii) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:331 or an amino acid sequence at least 90% identical thereto and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:332 or an amino acid sequence at least 90% identical thereto.
  • VH/VL combinations listed above, it is also permissible, and within the scope of the invention, to combine a VH domain having an amino acid sequence at least 90%, 92%, 95%, 97% or 99% identical to the recited VH domain sequence with a VL domain having an amino acid sequence at least 90%, 92%, 95%, 97% or 99% identical to the recited VL domain sequence.
  • Embodiments wherein the amino acid sequence of the VH domain exhibits less than 100% sequence identity with a given reference VH sequence may nevertheless comprise heavy chain CDRs which are identical to HCDR1 , HCDR2 and HCDR3 of the reference sequence whilst exhibiting amino acid sequence variation within the framework regions.
  • embodiments wherein the amino acid sequence of the VL domain exhibits less than 100% sequence identity with a given reference sequence may nevertheless comprise light chain CDRs which are identical to LCDR1 , LCDR2 and LCDR3 of the reference sequence whilst exhibiting amino acid sequence variation within the framework regions.
  • the structure of the antibodies/antigen binding fragments is defined on the basis of % sequence identity with a recited reference sequence (with a given SEQ ID NO).
  • % sequence identity between two amino acid sequences may be determined by comparing these two sequences aligned in an optimum manner and in which the amino acid sequence to be compared can comprise additions or deletions with respect to the reference sequence for an optimum alignment between these two sequences.
  • the percentage of identity is calculated by determining the number of identical positions for which the amino acid residue is identical between the two sequences, by dividing this number of identical positions by the total number of positions in the comparison window and by multiplying the result obtained by 100 in order to obtain the percentage of identity between these two sequences.
  • the comparison window with correspond to the full length of the sequence being compared.
  • BLAST 2 sequences “Tatusova et al, "Blast 2 sequences - a new tool for comparing protein and nucleotide sequences", FEMS Microbiol Lett.
  • sequence identity of a query sequence to a reference sequence is within the ability of the skilled person and can be performed using commercially available analysis software such as BLASTTM.
  • the antibody or antigen binding fragment may comprise a heavy chain variable domain and a light chain variable domain wherein HCDR1 comprises SEQ ID NO: 16, HCDR2 comprises SEQ ID NO: 17, HCDR3 comprises SEQ ID NO: 18, and LCDR1 comprises SEQ ID NO: 61 , LCDR2 comprises SEQ ID NO: 62, and LCDR3 comprises SEQ ID NO: 63.
  • the heavy chain variable domain may comprise the amino acid sequence shown as SEQ ID NO: 221 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto
  • the light chain variable domain may comprise the amino acid sequence shown as SEQ ID NO: 222 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto.
  • the heavy chain variable domain and light chain variable domain are the VH and VL domain of antibody 31282 provided herein.
  • Antibody 31282 provided herein is derived from antibody 29489.
  • Antibody 31282 was produced from 29489 by an M-T substitution at amino acid 1 16 in VH FR4 region. This substitution is understood to remove a potential oxidation site of the antibody and thereby improve stability without affecting function.
  • Antibodies 31282 and 29489 thus share identical HCDR1 , HCDR2, HCDR3, LCDR1 , LCDR2 and LCDR3 sequences, differing only in the framework.
  • the heavy chain variable domain may comprise the amino acid sequence shown as SEQ ID NO: 219 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto
  • the light chain variable domain may comprise the amino acid sequence shown as SEQ ID NO: 220 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto.
  • the heavy chain variable domain and light chain variable domain are the VH and VL domain of antibody 29489 provided herein.
  • Embodiments wherein the amino acid sequence of the VH domain exhibits less than 100% sequence identity with the sequence shown as SEQ ID NO: 221 or 219 may nevertheless comprise heavy chain CDRs which are identical to HCDR1 , HCDR2 and HCDR3 of SEQ ID NO:221 and 219 (SEQ ID NOs:16, 17 and 18, respectively) whilst exhibiting amino acid sequence variation within the framework regions.
  • embodiments wherein the amino acid sequence of the VL domain exhibits less than 100% sequence identity with the sequence shown as SEQ ID NO: 222 or 220 may nevertheless comprise light chain CDRs which are identical to LCDR1 , LCDR2 and LCDR3 of SEQ ID NO:222 and 220 (SEQ ID NOs:61 , 62 and 63, respectively) whilst exhibiting amino acid sequence variation within the framework regions.
  • Exemplary TIGIT antibodies described herein and having the sequences set out in Figure 1 -5 were developed from 5 parent antibody clones. Table 2 summarises the lineage of the antibodies described herein.
  • Naive parent human anti-TIGIT antibodies were expressed in yeast and those exhibiting high functional activity against TIGIT were selected (grey rows, named 26%), and underwent affinity maturation. Selected affinity-matured antibodies then were expressed in mammalian cells (white rows beneath each parent, named 29... or 3).
  • antibody 31282 was produced from 29489 by an M-T substitution at amino acid 1 16 in VH FR4 region. This substitution is understood to remove a potential oxidation site of the antibody and thereby improve stability without affecting function.
  • antibody 31288 was produced from 29494 by a V-L substitution at amino acid 2 in VH FR1 region and by an M-T substitution at amino acid 120 in VH FR4 region. The V-L substitution is understood to restore the sequence of VH4-39 germline and the M-T substitution to remove a potential oxidation site of the antibody and thereby improve stability without affecting function. Table 2
  • the second generation antibodies exhibit higher affinity than the respective parent antibodies.
  • the invention provides anti-TIGIT antibodies or antigen binding fragments thereof wherein the VH domain is derived from a human V region germline sequence selected from: VH3-07, VH3-30, VH1 -46, VH4-0B, VH4-39, VH1 -69, VH3-09, VH3-33, VH3-30.
  • the antibody or antigen binding fragment thereof comprises a VH domain derived from human V region germline VH1 -46.
  • a VH domain is "derived from" a particular V region germline sequence if the sequence of the heavy chain variable region is more likely derived from the given germline than from any other.
  • the invention also provides an antibody or antigen binding fragment thereof which binds to human TIGIT at an epitope comprising residues Q56 and 1109. In certain embodiments, the antibody or antigen binding fragment thereof binds human TIGIT at least at residues Q56, N58 and 1109. In certain embodiments, the antibody or antigen binding fragment thereof binds human TIGIT at an epitope comprising residues Q56, N58 and 1109 and optionally one or more of residues E60, I68, L73 and H76. In certain embodiments, the antibody or antigen binding fragment thereof binds human TIGIT at an epitope comprising residues Q56, N58, E60, I68, L73, H76, and 1109. In certain embodiments, the antibody or antigen binding fragment thereof binds to human TIGIT at an epitope consisting of TIGIT residues Q56, N58, E60, 168, L73, H76, and 1109. In certain
  • the antibody or antigen binding fragment thereof binds the same epitope as antibody 31282.
  • the antibody or antigen binding fragment binds an epitope of human TIGIT comprising the indicated TIGIT residues
  • the antibody binds each of these residues and optionally other residues of TIGIT.
  • the antibody or antigen binding fragment binds an epitope of human TIGIT consisting of TIGIT residues Q56, N58, E60, I68, L73, H76, and 1109
  • the antibody binds each of these residues and no other residues of TIGIT.
  • An antibody or antigen binding fragment binds to human TIGIT at a given epitope if it contacts the indicated TIGIT amino acid residue(s) when bound to TIGIT.
  • an antibody contacts a TIGIT residue if, when in the protein complex formed by antibody-TIGIT binding, the residue meets each of the following criteria: (i) it has a calculated binding free energy contribution greater than 0.3 kcal/mol, (ii) it has an experimental averaged B-factor lower than the mean B-factor of all residues in the X-ray structure, (iii) it makes at least 3 pairs of heavy-atom interatomic contacts with antibody atoms at a distance less than or equal to 4.0 Angstroms, (iv) it does not make only solvent-exposed hydrogen bond or ionic interactions, (v) if it is a non-aromatic polar residue (Asn, Gin, Ser, Thr, Asp, Glu, Lys, or Arg), it makes at least one hydrogen bond or ionic interaction with the
  • binding free energy is calculated using an empirical force field, preferably FoldX.
  • FoldX would be familiar to the skilled person and is publicly available at http://foldxsuite.crg.eu/. Calculation of binding free energy using FoldX is also described in Guerois et al. J. Mol. Biol.
  • heavy atoms are all non-hydrogen atoms (including C, N, O, S).
  • the invention also provides an antibody or antigen binding fragment thereof which contacts human TIGIT at least at residues Q56 and 1109.
  • the antibody or antigen binding fragment thereof contacts human TIGIT at least at residues Q56, N58 and 1109.
  • the antibody or antigen binding fragment thereof contacts human TIGIT at least at residues Q56, N58 and 1109 and optionally one or more of residues E60, I68, L73 and H76.
  • the antibody or antigen binding fragment thereof contacts human TIGIT at least at residues Q56, N58, E60, I68 L73, H76, and 1109.
  • the antibody or antigen binding fragment thereof contacts human TIGIT only at residues Q56, N58, E60, I68, L73, H76, and 1109.
  • Means for determining which residues of TIGIT are contacted by an antibody or antigen-binding fragment are familiar to the skilled person, including X-Ray crystallography, such as that described in Example 23.
  • an isolated antibody or antigen binding fragment thereof which binds to the same epitope as an antibody or antigen-binding fragment described herein.
  • TIGIT antibodies can take various different embodiments in which both a VH domain and a VL domain are present.
  • antibody herein is used in the broadest sense and encompasses, but is not limited to, monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g ., bispecific antibodies), so long as they exhibit the appropriate immunological specificity for a human TIGIT protein.
  • monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e. , the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes) on the antigen, each monoclonal antibody is directed against a single determinant or epitope on the antigen.
  • the TIGIT antibodies provided herein may comprise CH1 domains and/or CL domains, the amino acid sequence of which is fully or substantially human. If the TIGIT antibody is intended for human therapeutic use, it is typical for the entire constant region of the antibody, or at least a part thereof, to have fully or substantially human amino acid sequence.
  • one or more or any combination of the CH1 domain, hinge region , CH2 domain, CH3 domain and CL domain may be fully or substantially human with respect to its amino acid sequence.
  • Such antibodies may be of any human isotype, with human lgG4 and lgG1 being particularly preferred.
  • the CH1 domain , hinge region , CH2 domain, CH3 domain and CL domain may all have fully or substantially human amino acid sequence.
  • substantially human refers to an amino acid sequence identity of at least 90%, or at least 92%, or at least 95%, or at least 97%, or at least 99% with a human constant region.
  • human amino acid sequence in this context refers to an amino acid sequence which is encoded by a human immunoglobulin gene, which includes germline, rearranged and somatically mutated genes. Such antibodies may be of any human isotype, with human lgG4 and lgG1 being particularly preferred .
  • TIGIT antibodies comprising constant domains of "human" sequence which have been altered, by one or more amino acid additions, deletions or substitutions with respect to the human sequence.
  • the TIGIT antibodies provided herein may be of any isotype.
  • Antibodies intended for human therapeutic use will typically be of the IgA, IgD, IgE IgG, IgM type, often of the IgG type, in which case they can belong to any of the four sub-classes lgG1 , lgG2a and b, lgG3 or lgG4.
  • the TIGIT antibodies provided herein are IgG antibodies.
  • antibodies according to the invention are lgG1 antibodies.
  • antibodies according to the invention are lgG4 antibodies.
  • lgG4 antibodies are known to undergo Fab arm exchange (FAE), which can result in unpredictable pharmacodynamic properties of an lgG4 antibody. FAE has been shown to be prevented by the S228P mutation in the hinge region (Silva et al. J Biol Chem.
  • an antibody according to the invention is an lgG4 antibody
  • the antibody comprises the mutation S228P - that is, a serine to proline mutation at position 228 (according to EU numbering).
  • one or more amino acid substitutions, insertions or deletions may be made within the constant region of the heavy and/or the light chain , particularly within the Fc region.
  • Amino acid substitutions may result in replacement of the substituted amino acid with a different naturally occurring amino acid, or with a non-natural or modified amino acid.
  • Other structural modifications are also permitted, such as for example changes in glycosylation pattern (e.g . by addition or deletion of N- or O-linked glycosylation sites).
  • the TIGIT antibodies may comprise an Fc region of a given antibody isotype, for example human lgG1 , which is modified in order to reduce or substantially eliminate one or more antibody effector functions naturally associated with that antibody isotype.
  • a given antibody isotype for example human lgG1
  • antibodies with cell lytic effector functions can be effective at reducing Treg cell populations but, surprisingly, without adversely affecting conventional effector T cell populations. This selectivity can allow more potent inhibition of the regulatory effect of Tregs whilst retaining anti- tumour effector T cells.
  • the TIGIT antibodies retain one or more of the antibody effector functions naturally associated with that antibody isotype.
  • the TIGIT antibodies of the invention may be lgG1 antibodies that retain ADCC functionality.
  • the TIGIT antibodies may comprise an Fc region of a given antibody isotype, for example human lgG1 , which is modified in order to enhance one or more antibody effector functions naturally associated with that antibody isotype.
  • antibody effector functions include one or more or all of antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP).
  • ADCC antibody-dependent cellular cytotoxicity
  • CDC complement-dependent cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • the anti-TIGIT antibody is a modified antibody.
  • a bispecific antibody comprising a first arm specific for TIGIT and a second arm specific for a second target.
  • the second target is an immune checkpoint molecule.
  • the second target is OX40.
  • the second target is ICOS.
  • the second target is GITR.
  • the second target is 4-1 BB.
  • the second target is PD-1 .
  • the second target is PD-L1 .
  • the first arm specific of TIGIT comprises a combination of HCDR1 , HCDR2, HCDR3, LCDR1 , LCDR2 and LCDR3 sequences of an antibody according to the invention.
  • the first arm comprises comprise a heavy chain variable domain and a light chain variable domain wherein HCDR1 comprises SEQ ID NO: 16, HCDR2 comprises SEQ ID NO: 17, HCDR3 comprises SEQ ID NO: 18, and LCDR1 comprises SEQ ID NO: 61 , LCDR2 comprises SEQ ID NO: 62, and LCDR3 comprises SEQ ID NO: 63.
  • Monoclonal antibodies or antigen-binding fragments thereof that "cross-compete" with the TIGIT antibodies disclosed herein are those that bind human TIGIT at site(s) that are identical to, or overlapping with, the site(s) at which the present TIGIT antibodies bind. Competing monoclonal antibodies or antigen-binding fragments thereof can be identified, for example, via an antibody competition assay. For example, a sample of purified or partially purified human TIGIT can be bound to a solid support. Then, an antibody compound or antigen binding fragment thereof of the present invention and a monoclonal antibody or antigen-binding fragment thereof suspected of being able to compete with such invention antibody compound are added. One of the two molecules is labelled.
  • the labelled compound and the unlabelled compound bind to separate and discrete sites on TIGIT, the labelled compound will bind to the same level whether or not the suspected competing compound is present. However, if the sites of interaction are identical or overlapping, the unlabelled compound will compete, and the amount of labelled compound bound to the antigen will be lowered. If the unlabelled compound is present in excess, very little, if any, labelled compound will bind.
  • competing monoclonal antibodies or antigen-binding fragments thereof are those that decrease the binding of the present antibody compounds to TIGIT by about 50%, about 60%, about 70%, about 80%, about 85%, about 90%, about 95%, or about 99%. Details of procedures for carrying out such competition assays are well known in the art and can be found, for example, in Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory
  • Such assays can be made quantitative by using purified antibodies.
  • a standard curve is established by titrating one antibody against itself, i.e., the same antibody is used for both the label and the competitor.
  • the capacity of an unlabelled competing monoclonal antibody or antigen-binding fragment thereof to inhibit the binding of the labelled molecule to the plate is titrated. The results are plotted, and the concentrations necessary to achieve the desired degree of binding inhibition are compared.
  • the antibodies or antigen binding fragments of the invention exhibit high affinity for human TIGIT.
  • Fab fragments of the antibodies according to the invention exhibit a KD for TIGIT measured by ForteBioTM in the range of from 1x10 0 to 5x 10 ⁇ 8 M, optionally 7 x10 ⁇ 0 to 4 x 10 ⁇ 8 M.
  • antibodies according to the invention exhibit MSD KD in the range of from 1 x 10 "11 to 5 x 10 9 M, optionally 2 x 10 "11 to 1 x 10 9 .
  • Fab fragments of the antibodies according to the invention exhibit a KD for TIGIT measured by BiacoreTM in the range of from 1 x10 -10 M to 1x 10 -9 M, optionally 1 x10 - 0 to 7x 10 -10 M, optionally 2 x10 " 0 to 7 ⁇ 10 0 M.
  • an anti-TIGIT antibody or antigen binding fragment provided herein exhibits a binding EC50 for human TIGIT of less than 0.5 nM.
  • the antibody or antigen binding fragment exhibits a binding EC50 of from about 0.05 to about 0.4 nM, preferably from about 0.05 to about 0.3 nM, preferably from about 0.05 to about 0.2 nM, preferably from about 0.05 to about 0.15 nM .
  • the antibody or antigen binding fragment exhibits a binding EC50 for human TIGIT of about 0.1 nM.
  • the antibody comprises the CDRs of antibody 31282.
  • the EC50 is determined using Jurkat cells expressing human TIGIT, as described in Example 18.
  • antibodies or antigen binding fragments of the invention cross-react with mouse TIGIT and/or cynomolgus TIGIT. Since the "29" second generation antibodies are affinity matured progeny of the highly functional parent antibodies, it is expected that they will exhibit at least similar or equivalent functional properties as the parent antibodies, and vice versa.
  • an antibody or antigen binding fragment of the invention has equivalent affinity for TIGIT expressed by CD8 T cells and expressed by Treg cells.
  • an antibody or antigen binding fragment has "equivalent affinity" for CD8 T cells and Treg cells if the affinity for CD8 T cells is in the range of 0.5-1 .5 times that of the affinity for Treg cells.
  • an antibody having equivalent affinity for CD8 T cells and Treg cells which exhibits an affinity for Treg cells of 0.03 nM would exhibit an affinity for CD8 T cells in the range of 0.015- 0.045nM.
  • Table 3 provides a summary of the affinity properties of the anti-TIGIT antibodies of the invention, with grey cells indicating parent antibody clones, with second and third generation antibodies of each lineage shown immediately below the respective parent antibody (see also Table 2).
  • an anti-TIGIT antibody or antigen binding fragment provided herein exhibits a binding EC50 for human TIGIT of less than 0.5 nM.
  • the antibody or antigen binding fragment exhibits a binding EC50 of from about 0.05 to about 0.4 nM, preferably from about 0.1 to about 0.3 nM.
  • the antibody or antigen binding fragment exhibits a binding EC50 for human TIGIT of about 0.2 nM.
  • the antibody or antigen binding fragment comprises the CDRs of antibody 31282.
  • the EC50 is determined using CD8+ T cells from human PBMCs, preferably from a healthy individual, as described in Example 18.
  • antibodies or antigen binding fragment of the invention exhibit high affinity for TIGIT-expressing CD8 T cells and high affinity for TIGIT-expressing Treg cells.
  • antibodies or antigen binding fragment of the invention exhibit an affinity for TIGIT-expressing CD8 T cells and TIGIT-expressing Treg cells characterised by an EC50 less than 0.5nM, preferably less than 0.3nM, preferably less than 0.2nM.
  • the antibodies or antigen binding fragment of the invention exhibit equivalent affinity for TIGIT-expressing CD8 T cells and for TIGIT-expressing Treg cells.
  • Antibodies according to the invention e.g. antibody 31282 exhibit surprisingly high affinity for CD8+ T cells from cancer patients.
  • an anti-TIGIT antibody or antigen binding fragment provided herein exhibits a binding EC50 of less than 0.5 nM for human TIGIT on human CD8+ T cells from cancer patients.
  • the antibody or antigen binding fragment exhibits a binding EC50 of from about 0.05 to about 0.4 nM, preferably from about 0.1 to about 0.3 nM.
  • the antibody or antigen binding fragment exhibits an EC50 for human TIGIT of from about 0.1 nM to about 0.2 nM.
  • the antibody or antigen binding fragment comprises the CDRs of antibody 31282.
  • the EC50 is determined using CD8+ T cells from PBMCs taken from a patient with cancer, as described in Example 18.
  • antibodies or antigen binding fragments of the invention compete with CD155/PVR for TIGIT binding.
  • an antibody or antigen binding fragment of the invention exhibits competition with CD155 characterised by an IC50 of 0.2nM or less, preferably 0.1 nM or less. In certain embodiments, the antibody or antigen binding fragment exhibits competition with CD155 characterised by an IC50 of about 0.05 nM or less. In certain preferred embodiments, the exhibited IC50 is about 0.05 nM. Without wishing to be bound by theory, competition of antibodies with CD155 for TIGIT binding is expected to decrease levels of CD155-induced TIGIT-mediated signalling, thereby increasing levels of effector T cell activation.
  • the invention further provides "affinity variants" of the antibodies described herein.
  • the invention also provides an isolated antibody or antigen binding fragment thereof which cross- competes for binding to human TIGIT with an antibody or antigen-binding fragment described herein.
  • Antibodies according to the invention are surprisingly effective at promoting proinflammatory activity of CD8+ T cells.
  • antibodies or antigen binding fragments according to the invention are more effective at promoting pro- inflammatory CD8+ T cell activity (indicated by IFNg release) than comparator anti-TIGIT antibodies (see Figure 24).
  • This improved efficacy versus comparator antibodies was demonstrated in TIGIT- expressing transgenic Jurkat reporter cells and in primary CD8 T cells.
  • an anti-TIGIT antibody or antigen binding fragment provided herein exhibits an activation EC50 of less than 5 nM for human TIGIT expressed by Jurkat reporter cells as described in Example 19.
  • the antibody or antigen binding fragment exhibits an EC50 of from about 1 nM to about 4 nM, preferably from about 2 nM to about 4 nM.
  • an anti-TIGIT antibody or antigen binding fragment provided herein exhibits an activation EC50 of less than 0.4 nM for CD8 T cells from healthy individuals as described in Example 19.
  • CD8 T cell activity i.e. pro-inflammatory activity
  • the antibody or antigen binding fragment exhibits an EC50 of from about 0.05 nM to about 0.4 nM, preferably from about 0.1 nM to about 0.2 nM.
  • the EC50 is determined using CD8+ T cells from PBMCs taken from a healthy individual, as described in Example 19.
  • the provided anti- TIGIT antibodies are effective at increasing the activity of gamma-delta ( ⁇ , or g/d) T cells (i.e. T cells expressing the ⁇ TCR subunits, as opposed to the conventional ⁇ TCR subunits).
  • ⁇ T cells form a distinct and important component of the immune system and the ability of the antibodies provided herein to promote activity of these cells highlights the utility of the antibodies.
  • a method of promoting ⁇ T cell activity comprising contacting a population of ⁇ T cells with an anti-TIGIT antibody.
  • the method is performed in vitro.
  • the method is performed in vivo in a human subject.
  • the human subject has cancer.
  • the anti-TIGIT antibody or antigen binding fragment comprises a combination of HCDR1 , HCDR2, HCDR3, LCDR1 , LCDR2 and LCDR3 sequences of an antibody according to the invention.
  • the anti-TIGIT antibody comprises a heavy chain variable domain and a light chain variable domain wherein HCDR1 comprises SEQ ID NO: 16, HCDR2 comprises SEQ ID NO: 17, HCDR3 comprises SEQ ID NO: 18, and LCDR1 comprises SEQ ID NO: 61 , LCDR2 comprises SEQ ID NO: 62, and LCDR3 comprises SEQ ID NO: 63.
  • anti-TIGIT antibodies are able to selectively deplete TIGIT-expressing Treg cells. That is, anti-TIGIT antibodies reduce the proportion of TIGIT-expressing Treg cells relative to the total population of T cells to a greater extent than they reduce the proportion of effector or memory CD4 or CD8 T cells.
  • the antibody or antigen binding fragment thereof selectively depletes TIGIT- expressing Treg cells.
  • TIGIT-expressing Treg cells can be mediated via selective lysis of the TIGIT-expressing Tregs (e.g. by ADCC or CDC (see Figures 20, 21 , and 25).
  • TIGIT-expressing Tregs are understood to be the more potent regulatory cells than Tregs not expressing TIGIT.
  • selective depletion by lysis of TIGIT-expressing Treg cells is expected to increase T cell effector function (e.g. T-cell mediated cytotoxicity, pro-inflammatory cytokine release) by depleting the overall number of Treg cells but also depleting those Treg cells exhibiting the more potent regulatory function. This increased T cell effector function is demonstrated in Figure 24.
  • antibodies or antigen binding fragments of the invention selectively lyse TIGIT-expressing Treg cells.
  • Selective depletion of Treg cells expressing TIGIT can also be mediated by inducing internalisation of the TIGIT receptor such that it is no longer expressed at the cell membrane.
  • TIGIT+ Treg cells become TIGIT- Treg cells
  • the regulatory function of these cells is expected to become less potent (since TIGIT+ Tregs are more potent regulatory cells).
  • T cell effector function is expected to increase.
  • antibodies or antigen binding fragments of the invention inhibit suppressive activity of TIGIT-expressing Treg cells, preferably by inducing internalisation of TIGIT by TIGIT- expressing Treg cells. It is particularly advantageous for anti-TIGIT antibodies according to the invention to exhibit high affinity for CD8 T cells and Treg cells and also to exhibit selective depletion of Treg cells, thereby promoting T cell effector function via two mechanisms. Retention of antibody effector function (e.g. ADCC, CDC) results in effective depletion of the Tregs and the selectivity means the antibody effector function does not result in unwanted depletion of effector T cells.
  • ADCC antibody effector function
  • TIGIT antibodies of the invention exhibit affinity for effector T cells (e.g. CD8 T cells), TIGIT- mediated signalling in these cells can be inhibited by competition for CD155 binding and/or inducing internalisation of TIGIT on effector T cells. In combination, these effects of the antibodies of the invention can result in significant upregulation of T cell effector function.
  • antibodies and antigen binding fragments according to the invention include increasing the T cell effector function (e.g. release of
  • TILs tumour infiltrating lymphocytes
  • Exposure to the tumour microenvironment can lead to TILs exhibiting anergic or so-called “exhausted” phenotypes, possibly due to antigen over-exposure and/or an immunosuppressive tumour microenvironment.
  • Enhancing the effector function of TILs is desirable as it is these cells that are infiltrating the tumour itself and thus positioned at a locus best-suited to reduce tumour size or growth; however due to the anergic or exhausted phenotype of many TILs, it is expected to be difficult to potentiate their effector function.
  • the increase in proinflammatory response from TILs following exposure to antibodies of the invention is therefore surprising and indicates the antibodies may be particularly effective therapeutic agents.
  • Still further surprising advantageous properties exhibited by antibodies and antigen binding fragments include the ability to increase the pro-inflammatory activity of gamma-delta ( ⁇ ) T cells.
  • the ability to promote activity of non-conventional T cells such as ⁇ T cells has not previously been reported for an anti-TIGIT antibody and offers the potential to treat diseases other than cancer in which ⁇ T cells are known to be important.
  • ⁇ T cells have been reported to be involved in the response to pathogenic infection (bacterial, viral (e.g. CMV), fungal) as well as to have a role in protecting from autoimmune diseases.
  • the surprising ability to promote activity of non-conventional T cells provides further potency to the anti-tumour effects of the antibodies.
  • a method for selectively depleting Treg cells from a population of T cells comprising contacting the population of T cells with an anti-TIGIT antibody or antigen binding fragment thereof, whereby the anti-TIGIT antibody selectively depletes the population of Treg cells.
  • the method is performed in vitro.
  • the method is performed in vivo in a human subject.
  • the human subject has cancer.
  • the anti-TIGIT antibody or antigen binding fragment comprises a combination of HCDR1 , HCDR2, HCDR3, LCDR1 , LCDR2 and LCDR3 sequences of an antibody according to the invention.
  • the anti-TIGIT antibody comprises a heavy chain variable domain and a light chain variable domain wherein HCDR1 comprises SEQ ID NO: 16, HCDR2 comprises SEQ ID NO: 17, HCDR3 comprises SEQ ID NO: 18, and LCDR1 comprises SEQ ID NO: 61 , LCDR2 comprises SEQ ID NO: 62, and LCDR3 comprises SEQ ID NO: 63.
  • the present invention also provides anti-TIGIT antibodies that do not compete with CD155/PVR for TIGIT binding. Therefore, in a further aspect, the invention provides a human TIGIT antibody or antigen binding fragment thereof that does not compete with CD155/PVR for human TIGIT binding.
  • Fab fragments of the CD155 non-competitive anti-TIGIT antibodies according to the invention exhibit a KD for TIGIT measured by ForteBioTM in the range of from 5x10 9 to 5x10 8 M, optionally 1x10 8 to 3x10 8 M.
  • the antibody may comprise a heavy chain variable domain and a light chain variable domain wherein HCDR1 comprises SEQ ID NO: 280, HCDR2 comprises SEQ ID NO: 281 , HCDR3 comprises SEQ ID NO: 282, and LCDR1 comprises SEQ ID NO: 292, LCDR2 comprises SEQ ID NO: 293, and LCDR3 comprises SEQ ID NO: 294.
  • the heavy chain variable domain may comprise the amino acid sequence shown as SEQ ID NO: 333 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto
  • the light chain variable domain may comprise the amino acid sequence shown as SEQ ID NO: 334 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto.
  • Embodiments wherein the amino acid sequence of the VH domain exhibits less than 100% sequence identity with the sequence shown as SEQ ID NO: 333 may nevertheless comprise heavy chain CDRs which are identical to HCDR1 , HCDR2 and HCDR3 of SEQ ID NO:333 (SEQ ID NOs:280, 281 and 282, respectively) whilst exhibiting amino acid sequence variation within the framework regions.
  • amino acid sequence of the VL domain exhibits less than 100% sequence identity with the sequence shown as SEQ ID NO: 334 may nevertheless comprise light chain CDRs which are identical to LCDR1 , LCDR2 and LCDR3 of SEQ ID NO:334 (SEQ ID NOs:292, 293 and 294, respectively) whilst exhibiting amino acid sequence variation within the framework regions.
  • the antibody may comprise a heavy chain variable domain and a light chain variable domain wherein HCDR1 comprises SEQ ID NO: 353, HCDR2 comprises SEQ ID NO: 354, HCDR3 comprises SEQ ID NO: 355, and LCDR1 comprises SEQ ID NO: 356, LCDR2 comprises SEQ ID NO: 357, and LCDR3 comprises SEQ ID NO: 358.
  • the heavy chain variable domain may comprise the amino acid sequence shown as SEQ ID NO: 367 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto
  • the light chain variable domain may comprise the amino acid sequence shown as SEQ ID NO: 368 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% sequence identity thereto.
  • Embodiments wherein the amino acid sequence of the VH domain exhibits less than 100% sequence identity with the sequence shown as SEQ ID NO: 367 may nevertheless comprise heavy chain CDRs which are identical to HCDR1 , HCDR2 and HCDR3 of SEQ ID NO:367 (SEQ ID NOs:353, 354 and 355, respectively) whilst exhibiting amino acid sequence variation within the framework regions.
  • amino acid sequence of the VL domain exhibits less than 100% sequence identity with the sequence shown as SEQ ID NO: 368 may nevertheless comprise light chain CDRs which are identical to LCDR1 , LCDR2 and LCDR3 of SEQ ID NO:368 (SEQ ID NOs:356, 357 and 358, respectively) whilst exhibiting amino acid sequence variation within the framework regions.
  • the invention also provides polynucleotide molecules encoding the TIGIT antibodies of the invention, also expression vectors containing a nucleotide sequences which encode the TIGIT antibodies of the invention operably linked to regulatory sequences which permit expression of the antigen binding polypeptide in a host cell or cell-free expression system, and a host cell or cell-free expression system containing this expression vector.
  • Polynucleotide molecules encoding the TIGIT antibodies of the invention include, for example, recombinant DNA molecules.
  • nucleic acids or polynucleotides are "isolated”.
  • nucleic acid molecule when applied to a nucleic acid molecule, refers to a nucleic acid molecule that is separated from sequences with which it is immediately contiguous in the naturally occurring genome of the organism in which it originated.
  • an "isolated nucleic acid” may comprise a DNA molecule inserted into a vector, such as a plasmid or virus vector, or integrated into the genomic DNA of a prokaryotic or eukaryotic cell or non-human host organism.
  • RNA when applied to RNA, the term "isolated
  • polynucleotide refers primarily to an RNA molecule encoded by an isolated DNA molecule as defined above. Alternatively, the term may refer to an RNA molecule that has been purified/separated from other nucleic acids with which it would be associated in its natural state (i.e., in cells or tissues).
  • An isolated polynucleotide (either DNA or RNA) may further represent a molecule produced directly by biological or synthetic means and separated from other components present during its production.
  • a recombinant polynucleotide encoding it may be prepared (using standard molecular biology techniques) and inserted into a replicable vector for expression in a chosen host cell, or a cell-free expression system.
  • Suitable host cells may be prokaryote, yeast, or higher eukaryote cells, specifically mammalian cells.
  • useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol.
  • mice myeloma cells SP2/0-AG14 ATCC CRL 1581 ; ATCC CRL 8287) or NS0 (HPA culture collections no. 851 10503
  • monkey kidney cells CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumour (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y.
  • the term "host cell” generally refers to a cultured cell line. Whole human beings into which an expression vector encoding an antigen binding polypeptide according to the invention has been introduced are explicitly excluded from the definition of a "host cell”.
  • the invention also provides a method of producing a TIGIT antibody of the invention which comprises culturing a host cell (or cell free expression system) containing polynucleotide (e.g. an expression vector) encoding the TIGIT antibody under conditions which permit expression of the TIGIT antibody, and recovering the expressed TIGIT antibody.
  • This recombinant expression process can be used for large scale production of TIGIT antibodies according to the invention, including monoclonal antibodies intended for human therapeutic use. Suitable vectors, cell lines and production processes for large scale manufacture of recombinant antibodies suitable for in vivo therapeutic use are generally available in the art and will be well known to the skilled person.
  • an isolated polynucleotide or combination of isolated polynucleotides encoding an antibody or antigen binding fragment comprising a combination of HCDR1 , HCDR2, HCDR3, LCDR1 , LCDR2 and LCDR3, wherein the combination is selected from the group consisting of:
  • HCDR1 comprising SEQ ID NO: 16, HCDR2 comprising SEQ ID NO: 17, HCDR3 comprising SEQ ID NO:18, LCDR1 comprising SEQ ID NO:61 , LCDR2 comprising SEQ ID NO:62, and LCDR3 comprising SEQ ID NO:63;
  • HCDR1 comprising SEQ ID NO:4, HCDR2 comprising SEQ ID NO:5, HCDR3 comprising SEQ ID NO:6, LCDR1 comprising SEQ ID NO:49, LCDR2 comprising SEQ ID NO:50, and LCDR3 comprising SEQ ID NO:51 ;
  • HCDR1 comprising SEQ ID NO:7, HCDR2 comprising SEQ ID NO:8, HCDR3 comprising SEQ ID NO:9, LCDR1 comprising SEQ ID NO:52, LCDR2 comprising SEQ ID NO:53, and LCDR3 comprising SEQ ID NO:54;
  • HCDR1 comprising SEQ ID NO:10, HCDR2 comprising SEQ ID NO:11 , HCDR3 comprising SEQ ID NO:12, LCDR1 comprising SEQ ID NO:55, LCDR2 comprising SEQ ID NO:56, and LCDR3 comprising SEQ ID NO:57;
  • HCDR1 comprising SEQ ID NO:13, HCDR2 comprising SEQ ID NO:14, HCDR3 comprising SEQ ID NO:15, LCDR1 comprising SEQ ID NO:58, LCDR2 comprising SEQ ID NO:59, and LCDR3 comprising SEQ ID NO:60;
  • HCDR1 comprising SEQ ID NO:1 , HCDR2 comprising SEQ ID NO:2, HCDR3 comprising SEQ ID NO:3, LCDR1 comprising SEQ ID NO:46, LCDR2 comprising SEQ ID NO:47, and LCDR3 comprising SEQ ID NO:48;
  • HCDR1 comprising SEQ ID NO:19, HCDR2 comprising SEQ ID NO:20, HCDR3 comprising SEQ ID NO:21 , LCDR1 comprising SEQ ID NO:64, LCDR2 comprising SEQ ID NO:65, and LCDR3 comprising SEQ ID NO:66;
  • HCDR1 comprising SEQ ID NO:22, HCDR2 comprising SEQ ID NO:23, HCDR3 comprising SEQ ID NO:24, LCDR1 comprising SEQ ID NO:67, LCDR2 comprising SEQ ID NO:68, and LCDR3 comprising SEQ ID NO:69;
  • HCDR1 comprising SEQ ID NO:25, HCDR2 comprising SEQ ID NO:26, HCDR3 comprising SEQ ID NO:27, LCDR1 comprising SEQ ID NO:70, LCDR2 comprising SEQ ID NO:71 , and LCDR3 comprising SEQ ID NO:72;
  • HCDR1 comprising SEQ ID NO:28, HCDR2 comprising SEQ ID NO:29, HCDR3 comprising SEQ ID NO:30, LCDR1 comprising SEQ ID NO:73, LCDR2 comprising SEQ ID NO:74, and LCDR3 comprising SEQ ID NO:75;
  • HCDR1 comprising SEQ ID NO:31 , HCDR2 comprising SEQ ID NO:32, HCDR3 comprising SEQ ID NO:33, LCDR1 comprising SEQ ID NO:76, LCDR2 comprising SEQ ID NO:77, and LCDR3 comprising SEQ ID NO:78;
  • HCDR1 comprising SEQ ID NO:34, HCDR2 comprising SEQ ID NO:35, HCDR3 comprising SEQ ID NO:36, LCDR1 comprising SEQ ID NO:79, LCDR2 comprising SEQ ID NO:80, and LCDR3 comprising SEQ ID NO:81 ;
  • HCDR1 comprising SEQ ID NO:37, HCDR2 comprising SEQ ID NO:38, HCDR3 comprising SEQ ID NO:39, LCDR1 comprising SEQ ID NO:82, LCDR2 comprising SEQ ID NO:83, and LCDR3 comprising SEQ ID NO:84;
  • HCDR1 comprising SEQ ID NO:40, HCDR2 comprising SEQ ID NO:41 , HCDR3 comprising SEQ ID NO:42, LCDR1 comprising SEQ ID NO:85, LCDR2 comprising SEQ ID NO:86, and LCDR3 comprising SEQ ID NO:87;
  • HCDR1 comprising SEQ ID NO:43, HCDR2 comprising SEQ ID NO:44, HCDR3 comprising SEQ ID NO:45, LCDR1 comprising SEQ ID NO:88, LCDR2 comprising SEQ ID NO:89, and LCDR3 comprising SEQ ID NO:90;
  • HCDR1 comprising SEQ ID NO:271 , HCDR2 comprising SEQ ID NO:272, HCDR3 comprising SEQ ID NO:273, LCDR1 comprising SEQ ID NO:283, LCDR2 comprising SEQ ID NO:284, and LCDR3 comprising SEQ ID NO:285;
  • HCDR1 comprising SEQ ID NO:274, HCDR2 comprising SEQ ID NO:275, HCDR3 comprising SEQ ID NO:276, LCDR1 comprising SEQ ID NO:286, LCDR2 comprising SEQ ID NO:287, and LCDR3 comprising SEQ ID NO:288;
  • HCDR1 comprising SEQ ID NO:277, HCDR2 comprising SEQ ID NO:278, HCDR3 comprising SEQ ID NO:279, LCDR1 comprising SEQ ID NO:289, LCDR2 comprising SEQ ID NO:290, and LCDR3 comprising SEQ ID NO:291 .
  • polynucleotides encoding an antibody or antigen binding fragment comprising a combination of HCDR1 , HCDR2, HCDR3, LCDR1 , LCDR2 and LCDR3 wherein:
  • HCDR1 comprises or consists of SEQ ID NO: 16
  • HCDR2 comprises or consists of SEQ ID NO: 17
  • HCDR3 comprises or consists of SEQ ID NO:18
  • LCDR1 comprises or consists of SEQ ID NO:61
  • LCDR2 comprises or consists of SEQ ID NO:62
  • LCDR3 comprises or consists of SEQ ID NO:63.
  • an isolated polynucleotide or combination of isolated polynucleotides encoding an antibody or antigen binding fragment described herein.
  • an isolated polynucleotide encoding antibody 31282 provided herein, or an antigen binding fragment thereof is provided.
  • an isolated polynucleotide encoding a VH and/or a VL domain of an anti-TIGIT antibody, wherein the polynucleotide comprises one or more sequences selected from the group consisting of SEQ ID Nos: 241 -270, 335-342 and 369-370.
  • the isolated polynucleotide comprises a sequence according to SEQ ID NO: 251 and/or a sequence according to SEQ ID NO: 252.
  • polynucleotide comprises a sequence according to SEQ ID NO: 251 and a sequence according to SEQ ID NO: 252, the sequences are contiguous. In certain embodiments where the polynucleotide comprises a sequence according to SEQ ID NO: 251 and a sequence according to SEQ ID NO: 252, the sequences are not contiguous. Also, in accordance with the invention there is provided an expression vector comprising a polynucleotide according to the invention operably linked to regulatory sequences which permit expression of the antigen binding polypeptide in a host cell or cell-free expression system.
  • a host cell or cell-free expression system containing an expression vector according to the invention.
  • a method of producing a recombinant antibody or antigen binding fragment thereof which comprises culturing the host cell or cell free expression system according to the invention under conditions which permit expression of the antibody or antigen binding fragment and recovering the expressed antibody or antigen binding fragment.
  • compositions comprising an antibody or antigen binding fragment according to the invention formulated with one or more a pharmaceutically acceptable carriers or excipients.
  • Such compositions may include one or a combination of (e.g ., two or more different) TIGIT antibodies. Techniques for formulating antibodies for human therapeutic use are well known in the art and are reviewed, for example, in Wang et al., Journal of Pharmaceutical Sciences, Vol.96, pp1 -26, 2007.
  • TIGIT antibodies and pharmaceutical compositions provided herein have utility in therapy, in particular the therapeutic treatment of disease, in particular conditions that benefit from inhibition of TIGIT function.
  • the antibodies of the invention or antigen binding fragments thereof are particularly effective when administered in combination with immune checkpoint inhibitors - specifically anti-ICOS antagonist antibodies or anti-PD-1 antibodies (that is, antagonist antibodies specific for human immunoregulatory molecule PD-1 ).
  • immune checkpoint inhibitors - specifically anti-ICOS antagonist antibodies or anti-PD-1 antibodies that is, antagonist antibodies specific for human immunoregulatory molecule PD-1 .
  • Administration of anti-TIGIT antibodies in combination with an anti-ICOS or anti-PD-1 antibody results in a synergistic reduction in tumour growth compared to either antibody alone. Similar effects are expected to be observed using a combination of an anti-TIGIT antibody according to the invention and an anti-PD-L1 antibody.
  • antibodies of the invention or antigen binding fragments thereof are particularly effective when administered in combination with an agonist antibody specific to an immune checkpoint co-stimulatory molecule - specifically anti-4-1 BB, anti-OX40 or anti-GITR agonist antibodies.
  • Administration of anti-TIGIT antibodies in combination with an anti-4-1 BB, anti-OX40 or anti-GITR agonist antibody results in a synergistic reduction in tumour growth compared to either antibody alone.
  • a combination product comprising an anti-TIGIT antibody or antigen binding fragment thereof and one or more of a chemotherapeutic agent, an anti-PD1 antibody, an anti-PD-L1 antibody, an anti-41 BB antibody, an anti-OX40 antibody, an anti-GITR antibody, and an anti-ICOS antibody.
  • the anti-TIGIT antibody or antigen binding fragment is an antibody or antigen binding fragment provided in accordance with the invention.
  • the anti-TIGIT antibody or antigen binding fragment comprises a combination of HCDR1 , HCDR2, HCDR3, LCDR1 , LCDR2 and LCDR3, wherein:
  • HCDR1 comprises SEQ ID NO: 16 (YTFTSYYMH),
  • HCDR2 comprises SEQ ID NO: 17 (VIGPSGASTSYAQKFQG),
  • HCDR3 comprises SEQ ID NO: 18 (ARDHSDYWSGIMEV),
  • LCDR1 comprises SEQ ID NO: 61 (RASQS VRSSYLA) ,
  • LCDR2 comprises SEQ ID NO: 62 (GASSRAT), and
  • LCDR3 comprises SEQ ID NO: 63 (QQYFSPPWT). Also provided is a combination as provided herein for use in a method of treating cancer or viral infection, optionally wherein the viral infection is CMV infection. Further provided is a combination as provided herein for use in a method provided herein.
  • TIGIT antibodies, or antigen binding fragments thereof and pharmaceutical compositions provided herein can be used to inhibit the growth of cancerous tumour cells in vivo and are therefore useful in the treatment of tumours.
  • aspects of the invention relate to methods of inhibiting tumour cell growth in a human patient, and also methods of treating or preventing cancer, which comprise administering to a patient in need thereof an effective amount of a TIGIT antibody or antigen binding fragment as described herein, a pharmaceutical composition as described herein, or a combination as described herein.
  • Another aspect of the invention provides a TIGIT antibody or antigen binding fragment as described herein for use in inhibiting the growth of tumour cells in a human patient.
  • a still further aspect of the invention provides a TIGIT antibody or antigen binding fragment as described herein for use treating or preventing cancer in a human patient.
  • the invention provides a method of selectively depleting Treg cells in a cancer patient, the method comprising administering an anti-TIGIT antibody or antigen-binding fragment thereof to the patient.
  • the anti-TIGIT antibody binds at an epitope on human TIGIT comprising residues Q56, N58, E60, 168 L73, H76, and 1109, preferably consisting of residues Q56, N58, E60, I68 L73, H76, and 1109.
  • the anti-TIGIT antibody is an anti- TIGIT antibody provided herein.
  • the anti-TIGIT antibody comprises a combination of HCDR1 , HCDR2, HCDR3, LCDR1 , LCDR2 and LCDR3, wherein: HCDR1 comprises or consists SEQ ID NO: 16 (YTFTSYYMH), HCDR2 comprises or consists SEQ ID NO: 17 (VIGPSGASTSYAQKFQG), HCDR3 comprises or consists SEQ ID NO: 18 (ARDHSDYWSGIMEV), LCDR1 comprises or consists SEQ ID NO: 61 (RASQS VRSSYLA) , LCDR2 comprises or consists SEQ ID NO: 62 (GASSRAT), and LCDR3 comprises or consists SEQ ID NO: 63 (QQYFSPPWT).
  • HCDR1 comprises or consists SEQ ID NO: 16 (YTFTSYYMH)
  • HCDR2 comprises or consists SEQ ID NO: 17 (VIGPSGASTSYAQKFQG)
  • HCDR3 comprises or consists SEQ ID NO: 18 (ARDHS
  • the patient to be treated has a cancer selected from: renal cancer (e.g., renal cell carcinoma), breast cancer, brain tumours, chronic or acute leukaemias including acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphoblastic leukaemia, chronic lymphocytic leukaemia, lymphomas (e.g., Hodgkin's and non-Hodgkin's lymphoma, lymphocytic lymphoma, primary CNS lymphoma, B-cell lymphoma (e.g. CLL), T-cell lymphoma (e.g.
  • renal cancer e.g., renal cell carcinoma
  • breast cancer e.g., brain tumours
  • chronic or acute leukaemias including acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphoblastic leukaemia, chronic lymphocytic leukaemia, lymphomas (e.g., Hodgkin's and non-Hodgkin's lymph
  • nasopharyngeal carcinomas e.g., melanoma (e.g., metastatic malignant melanoma), prostate cancer, colon cancer, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck (e.g.
  • HNSCC head and neck squamous cell carcinoma
  • cutaneous carcinoma cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the oesophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, solid tumours of childhood, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), tumour angiogenesis, spinal axis tumour, brain stem glioma, pituitary adenoma, Kaposi's sarcom
  • the cancer is colon cancer (for example colon
  • the cancer is a blood cancer. In certain such embodiments, the cancer is lymphoma. In certain embodiments the cancer is T cell lymphoma or B cell lymphoma.
  • the method of treating cancer further comprises administration of an additional therapeutic agent, for example a chemotherapeutic agent.
  • an additional therapeutic agent for example a chemotherapeutic agent.
  • the antibodies of the invention or antigen binding fragments thereof are particularly effective when administered in combination with immune checkpoint inhibitors - specifically anti-ICOS antagonist antibodies or anti-PD-1 antibodies (that is, antagonist antibodies specific for human immunoregulatory molecule PD-1).
  • Administration of anti-TIGIT antibodies in combination with an anti-ICOS or anti-PD-1 antibody results in a synergistic reduction in tumour growth compared to either antibody alone. Similar effects are expected to be observed using a combination of an anti-TIGIT antibody according to the invention and an anti-PD-L1 antibody.
  • antibodies of the invention or antigen binding fragments thereof are particularly effective when administered in combination with an agonist antibody specific to an immune checkpoint co-stimulatory molecule - specifically anti-4-1 BB, anti-OX40 or anti-GITR agonist antibodies.
  • Administration of anti-TIGIT antibodies in combination with an anti-4-1 BB, anti-OX40 or anti-GITR agonist antibody results in a synergistic reduction in tumour growth compared to either antibody alone.
  • a method of treating cancer in a subject comprising administering to the subject an effective amount of an anti-TIGIT antibody or antigen binding fragment thereof according to the invention and also administering an effective amount of an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-41 BB antibody, an anti-OX40 antibody, and anti GITR antibody, or an anti-ICOS antibody.
  • ⁇ T cells are known to be important in the response to infection, for example bacterial, fungal or viral infection.
  • ⁇ T cells from CMV seropositive subjects exhibit markedly increased activation, characterised by an increase in IFNg section.
  • the ability to promote activation of ⁇ T cells in CMV patients in this manner indicates that administration of an anti-TIGIT antibody will promote the antiviral activity of the ⁇ T cells.
  • a method of treating viral infection in a subject comprising
  • the viral infection is CMV infection.
  • the method further comprises administration of one or more additional therapeutic agents.
  • the one or more therapeutic agents are selected from: an anti-PD1 antibody, an anti-PD-L1 antibody, an anti-41 BB antibody, an anti-OX40 antibody, an anti GITR antibody, and an anti-ICOS antibody.
  • the anti-TIGIT antibodies disclosed herein are effective at promoting T cell activity, especially pro-inflammatory T cell activity.
  • T ell activity can be measured by methods familiar to those of skill in the art, for example by measuring IFNg production as described in the Examples. Accordingly, also provided herein is_a method of promoting T cell activity comprising contacting a population of T cells with an antibody or antigen binding fragment as described herein.
  • the method of promoting T cell activity is performed in vitro. In certain embodiments, the method of promoting T cell activity is performed in vivo in a human subject. In certain such embodiments, the human subject has cancer. In certain embodiments, the human subject has a viral infection, for example CMV infection.
  • the method promotes conventional ⁇ T cell activity. In certain embodiments, the method promotes CD4 T cell activity. In certain embodiments, the method promotes CD8 T cell activity. In certain embodiments, the method promotes ⁇ (gamma-delta) T cell activity.
  • the anti-TIGIT antibodies disclosed herein will be especially effective at promoting T cell activity when used in combination with an anti-PD1 antibody, an anti-PD-L1 antibody, an anti-41 BB antibody, an anti-OX40 antibody, an anti GITR antibody, or an anti-ICOS antibody.
  • the combination provides a synergistic (i.e. greater than additive) increase in T cell activity.
  • the method of promoting T cell activity further comprises contacting the population of T cells with one or more of: an anti-PD1 antibody, an anti-PD-L1 antibody, an anti-41 BB antibody, an anti-OX40 antibody, an anti GITR antibody, and an anti-ICOS antibody.
  • TIGIT ABPs were selected from a synthetic library of human antibodies expressed and presented on the surface of yeast cells in IgG format generally as described, e.g., in WO2009036379;
  • yeast cells ⁇ 10 10 cells/library
  • FACS wash buffer phosphate-buffered saline (PBS)/0.1 % bovine serum albumin (BSA)
  • PBS wash buffer phosphate-buffered saline
  • BSA bovine serum albumin
  • yeast were pelleted, resuspended in 5 mL wash buffer, and loaded onto a Miltenyi LS column. After the 5 mL was loaded, the column was washed 3 times with 3 ml FACS wash buffer. The column was then removed from the magnetic field, and the yeast were eluted with 5 mL of growth media and then grown overnight. The following rounds of sorting were performed using flow cytometry. Approximately 1 10 8 yeast were pelleted, washed three times with wash buffer, and incubated with biotinylated TIGIT-Fc fusion antigen (10 nM) under equilibrium conditions at room temperature.
  • Yeast were then washed twice and stained with LC-FITC (diluted 1 :100) and either SA-633 (diluted 1 :500) or EA-PE (diluted 1 :50) secondary reagents for 15 min at 4°C. After washing twice with ice-cold wash buffer, the cell pellets were resuspended in 0.4 mL wash buffer and transferred to strainer-capped sort tubes. Sorting was performed using a FACS ARIA sorter (BD Biosciences) and sort gates were assigned to select for specific binders relative to a background control.
  • LC-FITC diluted 1 :100
  • SA-633 diluted 1 :500
  • EA-PE diluted 1 :50
  • naive clones was carried out utilizing three maturation strategies: light chain diversification; diversification of HCDR1 and HCDR2; and diversification of HCDR3 within the selected HCDR1 and HCDR2 diversity pools.
  • Light chain diversification Heavy chain variable regions were extracted from naive outputs (described above) and transformed into a light chain library with a diversity of 1 x 10 6 . Selections were performed as described above with one round of MACS sorting and three rounds of FACS sorting using 10 nM or 1 nM biotinylated TIGIT-HIS antigen (Creative Biomart) for respective rounds.
  • HCDR1 and HCDR2 selection The HCDR3s from clones selected from the light chain diversification procedure were recombined into a premade library with HCDR1 and HCDR2 variants of a diversity of 1 x 10 8 and selections were performed using monomeric HIS-TIGIT antigen. Affinity pressures were applied by using decreasing concentrations of biotinylated HIS-TIGIT antigen (100 to 1 nM) under equilibrium conditions at room temperature.
  • HCDR3/HCDR1/HCDR2 selections Oligos were ordered from IDT which comprised the HCDR3 as well as a homologous flanking region on either side of the HCDR3. Amino acid positions in the HCDR3 were variegated via NNK diversity at two positions per oligo across the entire HCHR3. The HCDR3 oligos were double-stranded using primers which annealed to the flanking region of the HCDR3. The remaining FWR1 to FWR3 of the heavy chain variable region was amplified from pools of antibodies with improved affinity that were isolated from the HCDR1 and HCDR2 diversities selected above.
  • the library was then created by transforming the double stranded HCDR3 oligo, the FWR1 to FWR3 pooled fragments, and the heavy chain expression vector into yeast already containing the light chain of the original na ' ive parent. Selections were performed as during previous cycles using FACS sorting for four rounds. For each FACS round the libraries were assessed for PSR binding, species cross-reactivity, and affinity pressure, and sorting was performed to obtain populations with the desired characteristics. Affinity pressures for these selections were performed as described above in the HCDR1 and HCDR2 selection.
  • yeast clones were grown to saturation and then induced for 48 h at 30°C with shaking. After induction, yeast cells were pelleted and the supernatants were harvested for purification. IgGs were purified using a Protein A column and eluted with acetic acid, pH 2.0. Fab fragments were generated by papain digestion and purified in a two steps process over Protein A (GE LifeSciences) and KappaSelect (GE Healthcare LifeSciences).
  • DNA vector coding for specific antibody clones were generated and transduced into HEK cells.
  • Human codon optimized synthetic DNA fragments for antibody variable domains were ordered at Geneart.
  • Variable domain sequences were seamlessly ligated into pUPE expression vectors containing the mouse IgKappa signal sequence and constant regions of the respective antibody class.
  • Expression vectors were verified by restriction analysis and DNA sequencing. For transient transfection Endotoxin free DNA maxipreps (Sigma) were produced and heavy and light chain vectors were co-transfected to HEK293EBNA1 cells, in Freestyle medium
  • the antibodies were further purified by gel-filtration using a Superdex200 column, equilibrated in PBS. Fractions were analysed by NuPAGE and antibody containing fractions were pooled. The final products were sterilized over a 0,22 ⁇ syringe filter. The product was analysed by NuPAGE and endotoxin levels were measured by LAL-assay.
  • Example 4 Affinity determination for binding of anti-TIGIT antibodies to recombinant human TIGIT protein
  • ForteBio KD measurements ForteBio affinity measurements of selected antibodies were performed generally as previously described (see, e.g., Estep et al., Mabs, Vol. 5(2), pp. 270-278 (2013)). Briefly, ForteBio affinity measurements were performed by loading IgGs on-line onto AHQ sensors. Sensors were equilibrated off-line in assay buffer for 30 min and then monitored on-line for 60 seconds for baseline
  • Biosensor analysis was conducted at 25 °C in a HBS-EP buffer system (10 mM HEPES pH 7.3, 150 mM NaCI, 3 mM EDTA, 0.05% Surfactant P20) using a Biacore 8K optical biosensor docked with a CM5 sensor chip (GE Healthcare, Marlboro, MA).
  • the sample hotel was maintained at 8°C.
  • Goat anti-human IgG capture antibody (Fey fragment specific, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA; 109-005-098) was immobilized (1 1700 +/- 200 RU) to both flow cells of the sensor chip using standard amine coupling chemistry. This surface type provided a format for reproducibly capturing fresh analysis antibody after each regeneration step.
  • Flow cell 2 was used to analyze captured antibody (60-90 RU) while flow cell 1 was used as a reference flow cell.
  • Antigen concentrations ranging from 30 to 0.123 nM (3-fold dilutions) were prepared in running buffer. Each of the antigen sample concentrations were run as a single replicate. Two blank (buffer) injections also were run and used to assess and subtract system artefacts. The association (300 s) and dissociation (600 s) phases for all antigen concentrations were performed at a flow rate of 30 uL/min. The surface was regenerated with three sequential injections (15 s, 15 s and 60 s) of 1 0 mM glycine, pH 1 .5 at a flow rate of 30 uL/min.
  • Example 5 Competition assay between anti-TIGIT antagonistic antibodies and TIGIT natural ligands A. Octet Red384 Epitope Binning/ligand blocking
  • Epitope binning/ligand blocking of selected antibodies was performed using a standard sandwich format cross-blocking assay. Control anti-target IgG was loaded onto AHQ sensors and unoccupied Fc-binding sites on the sensor were blocked with an irrelevant human lgG1 antibody. The sensors were then exposed to 100 nM target antigen (hTIGIT, Creative Biomart) followed by a second anti- target antibody or ligand (anti-TIGIT antibody and CD155 or CD1 13 or CD1 12). Data was processed using ForteBio's Data Analysis Software 7.0. Additional binding by the second antibody or ligand after antigen association indicates an unoccupied epitope (non-competitor), while no binding indicates epitope blocking (competitor or ligand blocking).
  • Parental antibodies (before optimization) were tested for competition with natural ligands and Table 6 summarizes the data obtained for competition against CD155, CD1 12 and CD1 13. Parental clone 26432 was found not to compete with CD155 for TIGIT binding. All other selected anti-TIGIT antibodies compete with natural ligand for binding to recombinant human TIGIT protein.
  • Jurkat cells overexpressing human TIGIT (Jurkat-hTIGIT) were collected and distributed at 10 5 cells/well and incubated with anti-human TIGIT antibodies at the following concentrations: 166,6 ; 53,24 ; 17,01 ; 5,43 ; 1 ,73 ; 0,55 ; 0,17 ; 0,05 ; 0,01 ; 5,78x10 3 ; 1 ,85x10 3 ; 5,9x10 3 nM in complete medium during 45 min at 37°C. Excess of antibody was washed, and then the cells were incubated with CD155-His at 5pg/ml (Creative Biomart, PVR-3141 H) for 45 min at 37°C.
  • Anti-TIGIT igG1 antibody samples were buffer exchanged into 1 M ammonium sulfate and 0.1 M sodium phosphate at pH 6.5 using a Zeba 40 kDa 0.5 mL spin column (Thermo Pierce, cat # 87766).
  • a salt gradient was established on a Dionex ProPac H!C-10 column from 1 .8 ammonium sulfate, 0.1 sodium phosphate at. pH 6.5 to the same condition without ammonium sulfate.
  • the gradient ran for 17 min at a flow rate of 0.75 mi/min.
  • An acetonitrile wash step was added at the end of the run to remove any remaining protein and the column was re-equilibrated over 7 column volumes before the next injection cycle.
  • Example 7 Characterization of PSR Preparation Polyspecificity reagent / . Preparation of Polyspecificity reagent :
  • Polyspecificity reagent was prepared according to Xu et.al, mAbs 2013. In brief, 2.5 liters CHO- S cells were used as starting material. The cells were pelleted at 2,400 x g for 5 min in 500 mL centrifuge bottles filled to 400 mL. Cell pellets were combined and then resuspended in 25 ml Buffer B and pelleted at 2,400 x g for 3 min. The buffer was decanted and the wash repeated one time. Cell pellets were resuspended in 3x the pellet volume of Buffer B containing 1 x protease inhibitors
  • the pellets containing the membrane fraction were retained and centrifuged at 40,000 for 20 min to remove residual supernatant.
  • the EMF pellets were then rinsed with Buffer B. 8 mL Buffer B was then added to the membrane pellets to dislodge the pellets and transfer into a Dounce Homogenizer. After the pellets were homogenized, they were transferred to a 50 mL conical tube and represented the final EMF preparation.
  • One billion mammalian cells e.g. CHO, HEK293, Sf9 at ⁇ 10 6 - 10 7 cells/mL were transferred from tissue culture environment into 4x 250 mL conical tubes and pelleted at 550 x g for 3 min. All subsequent steps were performed at 4 °C or on ice with ice-cold buffers. Cells were washed with 100 mL of PBSF (1x PBS + 1 mg/mL BSA) and combined into one conical tube.
  • PBSF 1x PBS + 1 mg/mL BSA
  • the cell pellet was then re-suspended in 30 mL Buffer B (50 mM HEPES, 0.15 M NaCI, 2 mM CaCI2, 5 mM KCI, 5 mM MgCI2, 10 % Glycerol, pH 7.2) and pelleted at 550 x g for 3 min. Buffer B supernatant was decanted and cells re-suspended in 3x pellet volume of Buffer B plus 2.5x protease inhibitor (Roche, complete, EDTA-free). Protease inhibitors in Buffer B were included from here on forward.
  • Buffer B 50 mM HEPES, 0.15 M NaCI, 2 mM CaCI2, 5 mM KCI, 5 mM MgCI2, 10 % Glycerol, pH 7.2
  • Solubilization Buffer 50 mM HEPES, 0.15 M NaCI, 2 mM CaCI2, 5 mM KCI, 5 mM MgCI2, 1 % n- Dodecyl-b-D-Maltopyranoside (DDM), 1 x protease inhibitor, pH 7.2
  • Solubilization Buffer 50 mM HEPES, 0.15 M NaCI, 2 mM CaCI2, 5 mM KCI, 5 mM MgCI2, 1 % n- Dodecyl-b-D-Maltopyranoside (DDM), 1 x protease inhibitor, pH 7.2
  • Biotinylation For biotinylation, prepare the NHS-LC-Biotin stock solution according to manufacturer's protocol (Pierce, Thermo Fisher). In brief, 20 ul of biotin reagent is added for every 1 mg of EMF sample and incubated at 4 °C for 3 hours with gentle agitation. Adjust the volume to 25 mL with Buffer B and transfer to an Oak Ridge centrifuge tube. Pellet the biotinylated EMF (b-EMF) at 40,000 x g for 1 hour, and rinse two times with 3 mL of Buffer C (Buffer B minus the glycerol) without disturbing the pellet. Remove the residual solution.
  • b-EMF biotinylated EMF
  • the pellet was re-suspended with a Dounce homogenizer in 3 mL of Buffer C as described previously.
  • the re-suspended pellet now represents biotinylated EMF (b- EMF) and is solubilized as described above to prepare b-SMPs.
  • b- EMF biotinylated EMF
  • PSR analyses were carried out generally as described in WO2014/179363. Briefly, to characterize the PSR profile of monoclonal antibodies presented on yeast, two million IgG-presenting yeast were transferred into a 96-well assay plate and pellet at 3000 x g for 3 min to remove supernatant. Re- suspend the pellet in 50 ul of freshly prepared 1 :10 dilution of stock b-PSRs and incubate on ice for 20 minutes. Wash the cells twice with 200 ul of cold PBSF and pellet re-suspended in 50 ul of secondary labeling mix (Extravidin-R-PE, anti-human LC-FITC, and propidium iodide).
  • secondary labeling mix Extravidin-R-PE, anti-human LC-FITC, and propidium iodide.
  • Example 8 Characterization of TIGIT expression on immune populations from healthy human PBMC
  • TIGIT expression profile on T cell subsets Flow cytometry analyses were performed to assess the expression of TIGIT on immune cell subsets in PBMC freshly isolated from healthy individuals. Conjugated antibodies were purchased from Ebioscience/Thermo Fisher Scientific, BioLegend or BD Biosciences. Cells were stained per manufacturer's instruction using filtered FACS buffer (PBS + 2mM EDTA + 0,1 %BSA) and Brilliant Stain buffer (BD #563794). Cells were blocked with appropriate Human FcBlock (BD #564220) prior to staining and were fixed using IC fixation buffer (eBioscience #00-8222-49) prior acquisition.
  • Conjugated antibodies were purchased from Ebioscience/Thermo Fisher Scientific, BioLegend or BD Biosciences. Cells were stained per manufacturer's instruction using filtered FACS buffer (PBS + 2mM EDTA + 0,1 %BSA) and Brilliant Stain buffer (BD #563794). Cells were blocked with appropriate Human FcBlock (
  • TIGIT is preferentially expressed on NK cells, regulatory T cells and CD8 memory T cells. It is present to a lesser extent on other T cells subsets with a low proportion of naive T cells showing TIGIT expression. In addition, TIGIT is not expressed on monocytes, dendritic cells and B cells (Fig.8B). This set of data is in agreement with published data (Yu et al. Nl 2008 and Wang et al. EJI 2015).
  • the affinity of human anti-TIGIT antibodies has been measured using Jurkat E6.1 cells transduced with human-TIGIT (Jurkat hTIGIT) or mouse TIGIT (Jurkat-mTIGIT).
  • 10 5 cells were distributed per well and incubated with anti- TIGIT antibody at a single dose of 100nM (Table 3) or with decreasing concentration (166,6 ; 53,24 ; 17,01 ; 5,43 ; 1 ,73 ; 0,55 ; 0,17 ; 0,05 ; 0,01 ; 5,78x10 3 ; 1 ,85x10 3 ; 5,9x10 3 nM ) of selected antibodies (Fig. 9).
  • Antibodies were incubated with the cells for 20 min at 4°C in FACS buffer. After washing, cells were incubated with anti-human Ig (Fc gamma specific)- PE (eBioscience, 12-4998-82, at 2 ⁇ g/ml) for 20min on ice and washed twice. Geometric mean fluorecence intensity was analysed using LSR BD Fortessa. Cell binding was recorded as the median florescence intensity of PE on the transfected line compared to the un-transfected line for each antibody (Table 3).
  • the half-maximal concentration of binding (EC50) to hTIGIT-Jurkat was calculated using a four-variable curve-fit equation in Prism, and the obtained values were the following ones: 0,082 nM for done 29489 ; 0,07 nM for clone 29494 ; 0,1 19 nM for clone 29520 and 0,05 nM for clone 29527 for the data illustrated in Fig.9.
  • the results demonstrate a strong binding to membrane expressed human TIGIT for the tested anti-TIGIT antibodies.
  • LVD efluor 520 eBioscience 65-0867-14
  • anti- TCRab-PercP-Cy5.5 Clone IP26, Biolegend 306723
  • anti-CD4-BV510 Clone SK3, BD Horizon 562970
  • anti-CD8-APC-Cy7 Clone SK1 , Biolegend 344714
  • anti-CD25-BV605 Clone 2A3, Biolegend 562660
  • anti-CD127-APC A019D5, Biolegend 351316)
  • anti-CCR7-BV421 Clone G043H7, Biolegend 353207
  • anti-CD45RO-PE-Cy7 Clone UCHL1 , Biolegend 304229
  • the EC50 value for binding to CD8 + human primary T cells was calculated using the % of positive TIGIT stained cells on gated LVD CD8 + T cells (Fig 10A and 10B).
  • the EC50 value for binding to human memory CD8 + or Treg primary T cells was calculated using the % of positive TIGIT stained cells on gated LVD TCRab + CD45RO + CD8 + T cells (for memory CD8 + T cells) or on gated LVD " TCRab + CD127'°CD25 hi CD4 + T cells (for Tregs) and are illustrated in Fig. 10C.
  • the EC50 value for binding to total human CD8 + T cells are 0,123nM for clone 29489; 0,181 nM, for clone 29520 and 0,253nM for clone 29527.
  • Direct comparison between 29489 and 31282 (the 29489 mutant with a M to T mutation on residue 1 16) was performed, and the EC50 value was 0,057 nM and 0,086 nM respectively, demonstrating strong and similar binding efficacy to human primary CD8 + T cells for the 2 clones (Fig 10B).
  • the EC50 values obtained for binding to memory CD8 + T cells and Treg were 0,039 nM and 0,03 nM respectively, demonstrating a strong and similar affinity for both populations (Fig. 10C).
  • Isolated PBMCs from Macaca fascicularis were obtained from BioPRIM. Cells were thawed and stimulated using the T cell activation/expansion kit for non-human primate (Miltenyi Biotec) at 1 :2 (bead:cell ratio) following the manufacturer's specifications. The next day, cells were collected, counted and distributed at 5x10 4 cells per well.
  • Fig 1 1A and 1 1 B anti-CD4- PercP-Cy5.5 (clone A161 A1 , BioLegend 357414); anti-CD8- BV510 (clone SK1 , BD Bioscience 563919), CD69-APC-Cy7 (Clone FN50, BioLegend, 310914) and LVD efluor 520 (eBioscience 65-0867-14). Stained cells were analysed by FACS using BD LSR Fortessa.
  • the EC50 value of binding was calculated using the % of positive TIGIT stained cells gated on LVD ⁇ CD69 + CD8 + T cells. As shown in Fig. 1 1 , the EC50 values for binding to cynomolgus CD8 + T cells were 0,487 nM for clone 29489, 1 ,73 nM for clone 29520 and 0,378 nM for clone 29527.
  • Clones 29489 and 31282 (the 29489 mutant with a M to T mutation on residue 1 16) were compared as well, and the EC50 values were 0,25 nM and 0,26 nM respectively for the example shown in Figure 1 1 B, demonstrating a similar and strong affinity for cynomolgus primary CD8 + T cells for the 2 clones.
  • Example 10 In vitro functional characterization of antagonistic anti-TIGIT activity
  • TIGIT-overexpressing Jurkat cells can be induced by contact with CD155-expressing CHO-K1 cells upon TCR engagement on Jurkat cells and can be increased in presence of antagonistic anti-TIGIT antibody.
  • the experiment was conducted in presence of increasing antibody concentrations and the EC50 values were calculated.
  • Thaw-and-Use CD155 aAPC/CHO-K1 (Promega, CS19881 1) cells were seeded according to manufacturer's recommendations and incubated at 37°C, 5% C02 incubator O/N. The day after, Thaw-and-Use TIGIT Effector cells (Promega, CS19881 1) were added according to manufacturer's recommendations to the CD155 aAPC/CHO-K1 cell plates containing fresh full medium with anti- TIGIT antibody at 133nM ( Figure 12A) or increasing concentrations (0,22; 0,54; 1 ,36; 3,41 ; 8,53; 21 ,3; 53,3; 133,33; and 333 nM) of anti-TIGIT antibody ( Figure 12B) and incubated at 37°C, 5% C02 during 6 hours.
  • TIGIT Effector cell was assessed by measuring the luciferase activity by using Bio-GloTM Luciferase Assay System (Promega, G7941).
  • Figure 12A shows the effect of the addition of the selected clones on Luciferase signal as compared to isotype control.
  • the data demonstrates the antagonistic activity of those antibodies that resulted in a stronger activation of Jurkat-hTIGIT cells.
  • Table 10 summarizes the fold change induction in luciferase expression obtained for the different anti-TIGIT antibodies over the isotype control clone (03847).
  • Table 10 Fold change induction over isotype control
  • Jurkat-hTIGIT cell activation was assessed with anti-TIGIT antibody between 0,22nM and 333nM and gave an ECso value of 3,0nM for clone 29489; 4,4nM for clone 29494; 2,3nM for clone 29520 and 32nM for clone 29527; 2,7nM for clone 32919 and 3,2nM for clone 32931 demonstrating a strong functional activity consecutive to blocking TIGIT inhibitory signalling.
  • Clones 29489 and 31282 (the 29489 mutant with a M to T mutation on residue 1 16) were compared as well, and the EC50 values were respectively of 4.3 nM and 8.1 nM for the example shown in Fig. 12C, demonstrating a similar functional activity for the 2 clones.
  • CD155 aAPC/CHO-K1 (Promega, CS19881 1) cells were seeded in U-bottom 96-well plates according to manufacturer's recommendations and incubated at 37°C, 5% C02 incubator O/N. The next day, CD8 + T cells were purified according to manufacturer's recommendations by using negative selection kit (Stemcell Technologies, 17953) from frozen human peripheral blood mononuclear cells isolated from total blood of healthy donors (Immunehealth).
  • CD8 T cells Purified CD8 T cells were then incubated with increasing concentrations (0,1 1 nM, 0,33nM, 1 ,06nM, 3,3nM, 10,6nM, 33,3nM, 105,5nM and 333 nM) of antibodies (100,000 CD8 T cells/1 OOul of full medium containing antibody) during 1 hour. After that, the antibody-CD8 mix was added to the CD155 aAPC/CHO-K1 cell plates containing 50 ⁇ of fresh full medium and incubated at 37°C, 5% C02 during 5 days. Finally, IFNg concentrations were assessed in cell supernatant using an ELISA assay (Affymetrix
  • CD155 aAPC/CHO-K1 (Promega, CS19881 1) cells were seeded in U-bottom 96-well plates according to manufacturer's recommendations and incubated at 37°C, 5% C02 incubator O/N. The next day, CD8 T cells were purified according to manufacturer's recommendations by using negative selection kit (Stemcell Technologies, 17953) from frozen human TILs isolated from ovarian ascites (Immunehealth). Purified CD8 + T cells were then incubated with anti-TIGIT antibody clone 26452, the non-optimized parent of clones 29489 and 31282 (100,000 CD8 + T cells/100 ⁇ of full medium containing antibody) during 1 hour. After that, the antibody-CD8 mix was added to the CD155 aAPC/CHO-K1 cell plates containing 50ul of fresh full medium and incubated at 37°C, 5% C02 during 5 days.
  • IFNg concentrations were assessed in cell supernatant using an ELISA assay (Affymetrix eBioscience, 88-7316-86) that was run according to manufacturer's recommendations. As seen in Figure 14, IFNg secretion was increased by almost 2 folds when anti-TIGIT antibody was added to the co-culture.
  • Example 11 Characterization of anti-TIGIT antagonistic antibody with functional activity in mouse A. Mouse CD155 competition assay for surrogate anti-TIGIT antagonistic antibody
  • Jurkat cells clone E6-1 , ATCC TIB-152
  • overexpress mouse TIGIT Jurkat-mTIGIT
  • Anti-TIGIT antibody 26493 was used as a surrogate as this antibody showed cross-reactivity for mouse TIGIT as well as binding to human TIGIT.
  • Cells were pre-incubated for 45min at 37°C with different concentrations of anti-TIGIT antibody clone 26493 (0.03 to 10 ⁇ g/ml) in 25 ⁇ of complete medium (RPMI + 10% FBS).
  • Fig. 15A shows the dose-response curve of anti- TIGIT clone 26493 for CD155 competition identifying 2,3nM as IC50 (upper dotted line represent signal from isotype, bottom dotted line signal from cells without CD155).
  • OT1 cells were isolated from the spleens of
  • TcraTcrb 1 100Mjb/Crl mice (Charles River) by mechanical dissociation followed by negative selection for mouse T cells using EasySepTM Mouse T Cell Isolation Kit (Stemcell, Catalog # 19851 ).
  • Pan02 cancer cells that naturally express CD155 were treated with Mitomycin C (25 ⁇ g/ml) and subsequently pulsed with OVA-peptide (S7951 -1 MG, Sigma Aldrich, 1 ⁇ g/ml, 1 h at 37°C).
  • CD8 + T cells and Pan02 were co-cultured for 3 days in the presence of anti- TIGIT clone 26493 or isotype control at 133nM.
  • the stimulated OT-1 CD8 + T cells were added at 1 x10 5 cells/well (effector cells) resulting in 10:1 effector to target ratio in the presence of anti-TIGIT clone 26493 or isotype control at 133nM. After 24hrs cells were washed with PBS and lifted by
  • Fig. 15B shows that anti-TIGIT antibody increases IFNg production by almost 2 folds while Fig. 15C shows an increased cytotoxic activity of mouse OT-I CD8 + T cells of around 60%. Altogether, these results confirm the functional activity of anti-TIGIT antibody to increase mouse CD8 + T cell effector function.
  • Example 12 Anti-tumour activity of anti-TIGIT antagonistic antibody in monotherapy and in combination with anti-PD1 antibodies in mouse model
  • anti-TIGIT clone 26493 was produced in mammalian cells on a mouse lgG2a isotype.
  • Female Balb/c mice of 8 weeks were inoculated with 500.000 CT26 colon cancer cells (ATCC® CRL-2638TM) subcutaneously.
  • CT26 colon cancer cells ATCC® CRL-2638TM
  • mice were treated with 200 ⁇ g of anti-TIGIT or with isotype control (mlgG2a, BioXcell) or with 200 ⁇ g of anti-PD-1 (RMP1 -14, BioXcell) and 200 ⁇ g of isotype control (mlgG2a, BioXcell) or with 200 ⁇ g of anti-PD-1 (RMP1 -14, BioXcell) and different concentrations of anti-TIGIT (200 ⁇ g, 60 ⁇ g, 20 ⁇ g) by intraperitoneal injections on day 9, day 12 and day 15. Tumor growth was monitored and tumor volumes were measured with electronic calipers three times a week from day 9 until day 36. Mice were sacrificed when tumor volume exceeded 2000mm 3 . Tumor growth curves were statistically analyzed by a linear mixed model.
  • Fig. 16A shows median tumor growth curves per group as well as individual growth curves for mice treated with anti-TIGIT antibody in monotherapy. Whereas in the control group, no mice had regression of the tumor, 2/8 mice treated with anti-TIGIT had a complete response. In the remaining mice, a clear tumor growth delay was present. In the control group, no mice survived beyond 30 days, whereas in the treated group, 7/8 mice survived beyond 30 days.
  • Fig. 16B shows median tumor growth curves per group as well as individual growth curves for mice treated by anti-PD1 in monotherapy or in combination with anti-TIGIT.
  • the combination of anti-TIGIT (at 200ug) and anti-PD1 antibodies resulted in 7/8 mice showing a complete response.
  • the anti-tumor efficacy was maintained with combination of anti-PD1 and lower doses of anti-TIGIT that achieve complete response for 8/8 mice when anti-TIGIT antibody was decreased to 60 ⁇ g and 5/8 mice when anti-TIGIT antibody was decreased further to 20 ⁇ g (Fig. 16C). These data demonstrate the significant anti-tumor efficacy of anti-TIGIT therapy in monotherapy (p ⁇ 0.0001) or in combination with an anti-PD1 antibody (p ⁇ 0.0001) for treatment of pre-established tumours.
  • Example 13 Isotype-dependent anti-tumour activity of anti-TIGIT antagonistic antibody in monotherapy and combination with anti-PD1 antibodies in mouse model.
  • anti-TIGIT clone 26493 was produced in mammalian cells on a mouse lgG2a and mouse lgG1 isotype.
  • mice were treated with 200 ⁇ g of anti-TIGIT or isotype control (mlgG2a, BioXcell) by intraperitoneal injections on day 10, day 13 and day 16.
  • mice were treated with 200 ⁇ g of anti-PD-1 (RMP1 -14, BioXcell) and 200 ⁇ g of isotype control (mlgG2a, BioXcell) or by combination of 200 ⁇ g of anti-PD-1 (RMP1 -14, BioXcell) and 200 ⁇ g of anti-TIGIT by intraperitoneal injections on day 10, day 13 and day 16.
  • Tumor growth was monitored and tumor volumes were measured with electronic calipers three times a week from day 10 until day 33. Mice were sacrificed when tumor volume exceeded 2000mm 3 .
  • tumours were analysed by flow cytometry for the immune cell infiltrate following treatment with anti-TIGIT antibody 26493 (lgG2a), in monotherapy and in combination with anti-PD-1 .
  • Mice were inoculated and treated as described in example 12. Two days after the second treatment, mice (8 mice per group) were sacrificed and tumours harvested. Tumours were dissociated with a tumour dissociation kit (Miltenyi Biotec).
  • Fig. 18A shows that in vivo treatment of tumour with anti-TIGIT mlgG2a antibody results in a decrease in proportion of regulatory T cells within CD4 + TILs population of 28% compared to the control group, which is not observed after treatment with anti-TIGIT mlgG1 .
  • Fig. 18B shows that there is no depletion of CD8 + TILs, but instead a small increase is observed for the two isotypes (a 17% increase compared to control for mlgG1 and 16% for mlgG2a).
  • Fig. 18G shows that combining anti-TIGIT mlgG2a with anti-PD-1 results in regulatory T cells being decreased by 33% compared to anti-PD-1 monotherapy.
  • CD8 + T cells the opposite is true, with 22% and 28% increase in CD8 + T cell infiltration, respectively for mlgG1 and mlgG2a isotypes, compared to anti-PD-1 monotherapy (Fig. 18H). Together, this results in more than two-fold increase in the CD8 + TILs to Treg ratio in the tumor for the combination with anti-TIGIT mlgG2a (Fig. 181).
  • treatment with anti-TIGIT antibody mlgG2a combined with anti-PD-1 demonstrates a shift in Th1 versus Th2 phenotype for intratumor CD4 + T cells, with a marked increase in IFNg producing CD4 cells (Fig. 18J) and a decrease in IL-10 producing CD4 cells (Fig. 18K). This resulted in a strong increase in IFNg/IL-10 producing cells after ex vivo stimulation in the CD4 + TILs population compared to mice treated with anti-PD-1 in monotherapy (Fig. 18L).
  • Table 12 Differentially expressed genes between anti-TIGIT mlgG2a + anti-PD-1 and anti-PD1 treated mice
  • Fig. 19A shows a volcano plot of the genes that are differentially regulated between vehicle treated mice and anti-TIGIT mlgG2a treated mice. Highly statistically significant genes fall at the top of the plot, and highly differentially expressed genes fall to either side (left: downregulated in anti-TIGIT treated mice, right: upregulated in anti-TIGIT treated mice). Examples of highly upregulated genes include perforin, granzyme B and CTLA-4.
  • the solid line represents a non-corrected p-value of 0.01 , the dotted line a corrected p-value of 0.05 (Benjamini-Hochberg correction).
  • Table 1 1 and Table 12 show the genes that were significantly differentially expressed for anti-TIGIT mlgG2a compared with vehicle and aPD-1 +anti-TIGIT mlgG2a versus anti-PD1 respectively.
  • Table 1 1 and Table 12 show the genes that were significantly differentially expressed for anti-TIGIT mlgG2a compared with vehicle and aPD-1 +anti-TIGIT mlgG2a versus anti-PD1 respectively.
  • Fig. 19B The same changes were present in mice treated with anti-PD-1 + anti-TIGIT mlgG2a compared to anti-PD-1 alone. No changes were observed in mice treated with anti-TIGIT mlgG1 , in monotherapy or in combination with anti-PD-1 .
  • Isolated PBMCs from healthy human donors were resuspended in complete RPMI medium
  • LVD efluor 520 eBioscience 65-0867-14
  • ant-TCRab- PercP-Cy5.5 Clone IP26, Biolegend 306723
  • anti-CD4-BV510 Clone SK3, BD Horizon 562970
  • anti-CD8-APC-Cy7 Clone SK1 , Biolegend 344714
  • anti-CD25-BV605 Clone 2A3, Biolegend 562660
  • anti-CD127-APC A019D5, Biolegend 351316)
  • anti-CCR7-BV421 Clone G043H7, Biolegend 353207
  • anti-CD45RO-PE-Cy7 Clone UCHL1 , Biolegend 304229
  • CD45 + CD4 + or CD45 + CD8 + represent the total CD4 + or CD8 + T cells.
  • CD45 + RO + CD4 + or CD45 + RO + CD8 + cells represent the memory CD4 + or CD8 + T cells while
  • CD25 hi CD127 low CD4 + represent Treg cells.
  • the proportion of TIGIT + cells on gated Tregs is higher than on gated memory CD8 + T cells and CD4 + T cells, as shown in Fig. 20A.
  • mice of 8 weeks were inoculated with 500.000 CT26 colon cancer cells (ATCC® CRL-2638TM) subcutaneously. Three weeks after inoculation, tumors were harvested and dissociated with a tumor dissociation kit (Miltenyi Biotec). The single cell suspension was incubated with 133nM anti-TIGIT antibody 26493 (mlgG1 or mlgG2a isotype) for 20h (1 million ⁇ 5/200 ⁇ in RPMI + 10%FBS).
  • Fig. 21 shows the % decrease in absolute TIGIT + cell counts compared to treatment with isotype control for the different TIGIT + immune subsets.
  • the strongest decrease after anti-TIGIT mlgG2a antibody treatment is evident in regulatory T cells (around 40% decrease), suggesting that these cells are more susceptible to ADCC than conventional CD4 + or CD8 + T cells.
  • EpiMatrix assessment scores above 1 .64 are defined as "hits"; that is to say potentially immunogenic and worthy of further consideration.
  • the EpiMatrix Protein Score is the difference between the number of predicted T cell epitopes expected to be found in a protein of a given size and the number of putative epitopes predicted by the EpiMatrix System.
  • EpiMatrix Protein Score is correlated with observed immunogenicity.
  • EpiMatrix Protein Scores are "normalized” and can be plotted on a standardized scale.
  • the EpiMatrix Protein Score of an "average" protein is zero.
  • EpiMatrix Protein Scores above zero indicate the presence of excess MHC ligands and denote a higher potential for immunogenicity while scores below zero indicate the presence of fewer potential MHC ligands than expected and a lower potential for immunogenicity. Proteins scoring above +20 are considered to have a significant immunogenic potential.
  • Antibodies are unique proteins in that the amino acid sequences of their variable domains, especially their Complementarity Determining Regions (CDRs), can vary to an extraordinary extent. It is this variability that allows antibodies to recognize a wide variety of antigens.
  • CDRs Complementarity Determining Regions
  • the recombination and mutation events that control antibody maturation can also produce new or neo- T cell epitopes. These neo-epitopes can appear to be "foreign" to circulating T cells.
  • the presence of neo-epitopes in antibody sequences can lead to the formation of a human-anti-human antibody response; also known as the HAHA response or ADA (Anti-Drug-Antibodies).
  • Regulatory T cells play an important role in suppressing immune responses to fully human proteins in the periphery, including those containing mutated and/or highly variable sequences such as antibody CDRs. Regulatory T cells are engaged and activated by regulatory T cell epitopes. The inherent risk associated with the presence of neo-epitopes in antibody sequences appears to be balanced by the presence of naturally occurring regulatory T cell epitopes.
  • the immunogenic potential of neo-epitopes contained in humanized antibodies can be effectively controlled in the presence of significant numbers of Tregitopes.
  • EpiVax has developed a Tregitope-adjusted EpiMatrix Score and corresponding prediction of anti-therapeutic antibody response.
  • the scores of the Tregitopes are deducted from the EpiMatrix Protein Score.
  • the Tregitope-adjusted scores have been shown to be well correlated with observed clinical immune response for a set of 23 commercial antibodies (De Groot et al. (2009) Clinical Immunol. 131 :189).
  • Clones 29489, 29494 and 31282 antibody sequences score on the low end of EpiMatrix scale, indicating limited potential for immunogenicity. Regression analysis of licensed monoclonal antibodies predicts ADA response in ⁇ 0% of exposed patients for antibody clone 29489 and 31282. For clone 29494, analysis predicts ADA response in 2.78% of exposed patients for the baseline VH sequence, and 2.88% for the variant VH sequence. Data are summarized in Table 13, below.
  • Example 17 Affinity determination for binding of anti-TIGIT clones to recombinant human
  • Antibody 31282 was compared against anti-TIGIT antibody clones described in other patent
  • VH SEQ ID NO: 34 of VH sequence:
  • VL SEQ ID NO: 36 of NSVTPEDTAVFYCTRESTTYDLLAGPFDYWGQGTLVTVSS WO2017/053748 (SEQ ID NO: 343 herein)
  • VL SEQ ID NO:9 of AADTAVYYCARDYYVSGNYYNVDYYFFGVDVWGQGTTVTVSS WO2016/106302 (SEQ ID NO: 345 herein)
  • VL SEQ ID NO: 130 of RSEDTAVYYCARGGPYGWYFDVWGQGTTVTVSS (SEQ ID NO:
  • VH sequence SEQ ID NO:67 of VH sequence:
  • VL SEQ ID NO:68 of WO2016/191643 ADTAVYYCARRQVGLGFAYWGQGTLVTVSS (SEQ ID NO: 349 herein)
  • TIG1 VH SEQ ID NO:10 of VH sequence:
  • VL SEQ ID NO:14 of SEDTAMYYCARMRLDYYAMDYWGQGTSVTVSS (SEQ ID NO: WO2017/152088 351 herein)
  • DNA vectors coding for specific antibody clones (clones 31282_up, 4.1 D3, 22G2, 31 C6, 313M32 and TIG1) were generated and transduced into HEK cells for production of human lgG1 isotype.
  • Human codon optimized synthetic DNA fragments for antibody variable domains were ordered at Geneart.
  • Variable domain sequences were seamlessly ligated into pUPE expression vectors containing the mouse
  • IgKappa signal sequence and constant regions of the respective antibody class were verified by restriction analysis and DNA sequencing.
  • Endotoxin free DNA maxipreps (Sigma) were produced and heavy and light chain vectors were co-transfected to
  • HEK293EBNA1 cells in Freestyle medium (ThermoFisherScientific), according to established
  • Antibodies were eluted with 20 mM Citrate 150 mM NaCI pH3 and neutralized to approximately pH7 with 1/6 volume of 1 M K2HP04/KH2P04 pH8.
  • the antibodies were further purified by gel-filtration using a Superdex200 column, equilibrated in PBS. Fractions were analysed by NuPAGE and antibody containing fractions were pooled. The final products were sterilized over a 0,22 ⁇ syringe filter. The product was analysed by NuPAGE and endotoxin levels were measured by LAL-assay.
  • clone 31282 was also produced in CHO-K1 cell as follow (clone 31282_wu) on lgG1 or lgG4 isotype.
  • DNA vectors coding for the antibodies were constructed and transfected into CHO-K1 cells.
  • CHO codon optimized DNA fragments for antibody variable domains were synthesized, and ligated into expression vectors containing the signal sequence and constant regions of the respective antibody class.
  • Expression vectors were verified by restriction analysis and DNA sequencing.
  • Heavy and light chain vectors were co-transfected to CHO-K1 cells by electroporation (Bio-rad) according to established protocols. The transfected cultures were scaled up and inoculated into fed-batch cultures. Conditioned medium was harvested after 14 days of fed-batch cultures.
  • the CEX column was equilibrated in 50 mM NaAc-HAc (pH 5.5), and the antibodies were eluted out by linear gradient elution (LGE) to reach 50 mM NaAc-HAc (pH 5.5) containing 0.5 M NaCI in 10 CV .
  • LGE linear gradient elution
  • the final ultrafiltration and dia-filtration (UF/DF) using Pellicon 3, ultracel 30 kD, type A (Millipore) was performed to concentrate the CEX eluate and exchange buffer into 20 mM His-HCI (pH 5.5).
  • Example 18 Cellular binding of anti-TIGIT antagonistic antibodies
  • the affinity of human anti-TIGIT antibodies has been measured using Jurkat E6.1 cells transduced with human-TIGIT (Jurkat hTIGIT).
  • 10 5 cells were distributed per well and incubated with decreasing concentration (8; 4; 2; 1 ; 0,5; 0,25; 0,125; 0,062; 0,031 ; 0,016; 8x10 3 and 4x10 3 nM) of various anti-TIGIT antagonist antibody clones (Fig. 2).
  • Antibodies were incubated with the cells for 20 min at 4°C in FACS buffer.
  • EC50 values for binding Jurkat-hTIGIT are very close for clone 31282 with no marked difference between antibody produced in HEK cells (31282_up, 0.13nM) or in CHO-K1 cells (31282-wu, 0.1 OnM).
  • Clone 31 C6 and TIG1 also show EC50 values below 0.2nM while affinity for other clones (4.1 D3, 22G2 and 313M32) is lower and results show EC50 values ranging from 0.267 to 0.445 nM.
  • Results demonstrate a strong binding to membrane expressed human TIGIT in an engineered system for anti-TIGIT clones 31282, 31 C6 and TIG1 while other clones have a lower affinity.
  • Table 16 EC50 data and comparison of different a-TIGIT clones for binding to Jurkat-hTIGIT
  • Isolated human PBMCs from healthy volunteers were analysed for binding by antagonist anti-TIGIT antibodies.
  • Cells were distributed at 1x10 5 cells per well.
  • Cells were incubated with anti-CD16 (Clone 3G8, BioLegend 302002), CD32 (Clone FLI8.26, BD Bioscience 557333) and CD64 (BD Bioscience 555525) at room temperature for 10 min, and the indicated anti-human TIGIT antibody clones were directly added at a final concentration of 8; 4; 2; 1 ; 0,5; 0,25; 0,125; 0,062; 0,031 ; 0,016; 8x10 3 and 4x10 3 nM in FACS buffer and incubated for 20 min at 4°C.
  • EC50 values for binding to CD8 + human primary T cells were calculated using the MFI signal on living TIGIT + CD8 + T cells. The results are illustrated in Figure 22B and the EC50 concentrations summarized in the Table 17 below. EC50 values for binding human primary CD8 + T cells are very close for clone 31282 with no marked difference between antibody produced in HEK cells (31282_up, 0.21 nM) or in CHO-K1 cells (31282-wu, 0.19nM). Comparison between the different clones of antagonist a-TIGIT antibodies show the best EC50 value for binding on human primary CD8 + T cells for done 31282_wu (0.19 nM) and clone 31282_up (0.21 nM).
  • Clones 31 C6 and TIG1 show a difference in EC50 of 2 fold while clone 22G2, 313M32 and 4.1 D3 differs by a factor of 6.1 to 9.7 fold.
  • 31282_wu and 31282_up show the best binding to membrane expressed TIGIT on human primary CD8+ T cells.
  • Table 17 EC50 data and comparison of different a-TIGIT clones for binding to Human primary CD8 + T cells
  • Isolated human PBMCs from cancer patients were analysed for binding by different antagonist anti- TIGIT antibody clones.
  • Cells were distributed at 1x10 5 cells per well.
  • Cells were incubated with anti- CD16 (Clone 3G8, BioLegend 302002), CD32 (Clone FLI8.26, BD Bioscience 557333) and CD64 (BD Bioscience 555525) at room temperature for 10 min, and the indicated anti-human TIGIT antibodies were directly added at a final concentration of : 8, 4, 2, 1 , 0.5, 0.25, 0.125, 0.062 and 0.031 nM in FACS buffer and incubated for 20 min at 4°C.
  • Clones 31282_wu and 31282_up show very close EC50 value for binding on CD8 + T cells from cancer patients with concentration of 0.14 and 0.12 nM, respectively.
  • the rest of the clones show lower affinity with clone 31 C6, TIG1 and 22G2 showing a 1 .5, 2.7 and 3.1 fold lower affinity, respectively.
  • Measured EC50 value for clone 313M32 is 8.3 fold lower compared to clone 31282_up.
  • Clone 4.1 D3 shows the lowest affinity, binding with a difference of 9.5 fold to the best clone tested.
  • Table 18 EC50 data and comparison of different a-TIGIT clones for binding to Human primary CD8 + T cells from cancer patients
  • Example 19 Competition assay between anti-TIGIT antagonist antibody clones and TIGIT natural ligand (CD155)
  • Jurkat cells overexpressing human TIGIT (Jurkat-hTIGIT) were collected and distributed at 5.10 4 cells/well and incubated with anti-human TIGIT antibodies at the following concentrations: 133,33; 42,20; 13,33; 4,22; 1 ,33; 0,422; 0,133; 0,042; 0,0133; 4,2x10 3 ; 1 ,3x10 3 ; 4,2x10 4 ; 1 ,3x10 4 ; 4,2x10 " 5 nM in complete medium during 45 min at 37°C. Excess of antibody was washed, and then the cells were incubated with CD155-His at ⁇ g/ml (Creative Biomart, PVR-3141 H) for 45 min at 37°C.
  • CD155-His was detected using anti-His tag-PE (Biolegend, 362603, at 2 ⁇ per test), incubated for 30 min at 4°C.
  • Cells were analysed by FACS using BD LSRFortessa and the half concentration (IC50) that prevents CD155 binding was calculated based on the median fluorescence intensity of PE in total cells. The results are illustrated in Figure 23 and the values summarized in the Table 19 below.
  • Anti-TIGIT clones 31282_wu and 31282_up show the best IC50 values for CD155 competition on Jurkat cells engineered to express hTIGIT with concentration of 0.05 and 0.04nM respectively.
  • Table 19 ICso data and comparison of different a-TIGIT clones for CD155 competition on human TIGIT
  • TIGIT-overexpressing Jurkat cells can be induced by contact with CD155-expressing CHO-K1 cells upon TCR engagement on Jurkat cells and can be increased in presence of antagonist anti-TIGIT antibody.
  • the experiment was conducted in presence of increasing antibody concentrations and the EC50 values were calculated.
  • CD155 aAPC/CHO-K1 (Promega, CS19881 1) cells were seeded according to manufacturer's recommendations and incubated at 37°C, 5% C02 incubator O/N. The next day, TIGIT Effector cells (Promega, CS19881 1) were added according to manufacturer's recommendations to the CD155 aAPC/CHO-K1 cell plates containing fresh full medium with anti-TIGIT antibody at increasing concentrations (0,03; 0,1 1 ; 0,33; 1 ,06; 3,34; 10,56; 33,38; 105,49; and 333 nM) and incubated at 37°C, 5% C02 during 6 hours. After the 6 hours of incubation, activation of TIGIT Effector cell was assessed by measuring the luciferase activity by using Bio-GloTM Luciferase Assay System
  • anti-TIGIT antibody 31282 has the best efficacy in term of EC50 value and maximum induction of luciferase signal in the assay.
  • Activity observed for clone produced in HEK (31282_up) or CHO-K1 (31282_wu) cells is comparable with a maximum luciferase signal that is 8 folds higher than control isotype (Bioexcell, BE0297) and with an EC50 concentration measured at 3.3nM and 3.5nM respectively.
  • clones 4.1 D3, 22G2 and 31 C6 have a maximum activity between 5.3 and 6.7 fold over isotype control, associated with an EC50 between 5 and 10nM.
  • EC50 values for clone 313M32 and TIG1 could not be determined due to a low activity and poor fitting of the curves at the concentrations tested ( Figure 24A).
  • Table 20 EC50 data and comparison of different a-TIGIT clones for functional activity on Jurkat-hTIGIT cells
  • CD155 aAPC/CHO-K1 (Promega, CS19881 1) cells were seeded in U-bottom 96-well plates according to manufacturer's recommendations and incubated at 37°C, 5% C02 incubator O/N. The next day, CD8 + T cells were purified according to manufacturer's recommendations by using negative selection kit (Stemcell Technologies, 17953) from frozen human peripheral blood mononuclear cells isolated from total blood of healthy donors (Immunehealth).
  • CD8 T cells and increasing concentrations (0,01 1 nM, 0,033nM, 0,1 1 nM, 0,33nM, 1 ,06nM, 3,3nM, 10,6nM, 33,3nM and 105, 5nM) of antibodies were then added to CD155 aAPC/CHO-K1 (100,000 CD8 T cells/1 OOul of full medium containing antibody) and incubated at 37°C, 5% C02 during 5 days. Finally, IFNg concentrations were assessed in cell supernatant using an ELISA assay (Affymetrix eBioscience, 88-7316-86) that was run according to manufacturer's recommendations.
  • ELISA assay Affymetrix eBioscience, 88-7316-86
  • a-TIGIT clone 31282 and 4.1 D3 display the best induction of IFNg secretion with a respective 2.7 and 2.9 fold increase over isotype control antibody.
  • Clone 31282 has the best efficacy for induction of IFNg production in terms of EC50 concentration, which was measured at 0.13nM.
  • Clone 31 C6 shows an EC50 value 2.3 fold different while clone 22G2 and 4.1 D3 are 3.1 and 10.8 fold less potent than clone 31282. No value could be determined for done 313M32 due to a low activity and poor fitting of the curves at the concentrations tested ( Figure 24 B).
  • Table 21 EC50 data and comparison of different a-TIGIT clones for functional activity on human primary CD8 + T cells
  • human primary CD3 + T cells from PBMC of a cancerous patient were co-cultured with a CHO-K1 cell line engineered to express human PVR/CD155 and to activate human T cells (CHO- TCR-CD155).
  • CHO- TCR-CD155 a CHO-K1 cell line engineered to express human PVR/CD155 and to activate human T cells
  • CD155 aAPC/CHO-K1 (Promega, CS19881 1) cells were seeded in U-bottom 96-well plates according to manufacturer's recommendations and incubated at 37°C, 5% C02 incubator O/N. The day after, CD3 + T cells were purified according to manufacturer's recommendations by using negative selection kit (Stemcell Technologies, 17951 ) from fresh human peripheral blood mononuclear cells isolated from total blood from a cancerous patient (HNSCC) collected 24h earlier (Biopartners).
  • HNSCC cancerous patient
  • CD155 aAPC/CHO-K1 100,000 CD3 T cells/1 OOul of full medium containing antibody
  • IFNg concentrations were assessed in cell supernatant using an ELISA assay (Affymetrix
  • antibody 31282 induced a strong functional activity to increase IFNg secretion, demonstrating the potential of this a-TIGIT antibody to reactivate PBMC T cells from cancer patients.
  • DTC dissociated tumour cells
  • Cytokine-secreting T cells were gated using unstained and unstimulated controls.
  • Figure 24D shows that intracellular content of IL2, IFNg and TNFa were all increased upon activation in presence of a-TIGIT clone 31282. This increase was observed in CD3 + T cells from PBMC in accordance with data illustrated in Figure 24C but also in both CD4 + and CD8 + TIL from dissociated tumour cells. This demonstrates the potential of a-TIGIT clone 31282 to increase the activation of PBMC and TIL populations from cancer patient T cells.
  • Example 21 a-TIGIT clone 31282 induces preferential cytotoxicity of Treg in PBMC from cancer patients
  • isolated PBMCs from a lung cancer patient were resuspended in complete RPMI medium (supplemented with 10% FBS heat inactivated + 50U Penicillin + 50 U Streptomycin).
  • 2.5x10 5 human PBMCs were distributed per well in 96U well plate.
  • Anti-human TIGIT antibody clone 31282, human lgG1 isotype control (BioXcell BE0297) or Rituximab (InvivoGen hcd20-mab1) were added at a final concentration of 6.6nM to each corresponding well. Cells were incubated for 20h at 37°C with 5% C02.
  • anti-TIGIT clone 31282 triggers higher specific lysis on Tregs cells (30.1 +/- 3 %) than on CD45RO + CCR7 +/ CD8 + T cells (total memory CD8 + T cells) (-1 .48 +/- 6 %) or
  • CD45RO + CCR7 +/ CD4 + T total memory CD4 + T cells (0.64+/- 3 %).
  • Rituximab positive control triggers 77.9% (+/- 6.8%) of specific lysis on gated CD19 + cells.
  • Overall data demonstrate a preferential depletion of Treg cells from cancer patient PBMC as compared to total memory CD4 + and CD8 + T cell populations. Similar preferential depletion of Treg cells was observed using cells from a patient with colon adenocarcinoma.
  • DTC dissociated tumour cells
  • FcBlock (BD #564220) prior to staining and were fixed using IC fixation buffer (eBioscience #00-8222- 49) prior acquisition.
  • DTC were stained with the following antibody panel: anti-CD45-BB515 (Clone HI30, BD Horizon 564585), anti-CD73-BV421 (Clone AD2, BD Horizon 562430), anti-CD8a-BV510 (Clone SK1 , BD Horizon 563919), anti-CD3-BV650 (Clone SK7, BD Horizon 563999), anti-CD56- BV71 1 (Clone 5.1 H1 1 , Biolegend 362542), anti-CD279-BV785 (Clone EH12.2H7, Biolegend 329930), anti-CD127-APC (Clone A019D5, Biolegend 351316), anti-CD4-APC-R700 (Clone RPA-T4, BD Horizon 564975), LVD efluor 780 (
  • PBMC peripheral blood mononuclear cells
  • anti-CD45RO-BB515 (Clone UCHL1 , BD Horizon 564529), anti-CD73-BV421 (Clone AD2, BD Horizon 562430), anti-CD8a-BV510 (Clone SK1 , BD Horizon 563919), anti-CD3-BV650 (Clone SK7, BD Horizon 563999), anti-CD56-BV71 1 (Clone 5.1 H1 1 , Biolegend 362542), anti-CD197-BV786 (Clone 3D12, BD Horizon 563710), anti-CD127-APC (Clone A019D5, Biolegend 351316), anti-CD4-APC- R700 (Clone RPA-T4, BD Horizon 564975), LVD efluor 780 (eBioscience 65-0865-14), anti-TIGIT-PE (Clone MBSA43, eBioscience E13456-108), anti-CD39-
  • CD3 + CD4 + CD127 + CD25 CD3 + CD4 + non-Treg cells
  • CD3 + CD4 + CD127' 0W CD25 + regulatory T cells
  • CD3 + CD8 + CD3 + CD8 + T cells
  • CD3 + CD56 + (NKT cells) CD3 " CD56 " (non-T/NK cells).
  • Quantibrite PE beads (BD #340495) were run at the same instrument settings and used to convert fluorescence data into number of antibodies bound per cell. Frequency of TIGIT expression on different immune populations is represented in Figure 26A and TIGIT density for each subset is represented in Figure 26B using Box and whiskers representation using the Tukey method to compute percentiles.
  • TIGIT frequency on T cell subset is higher on PBMC from cancer patients as compared to PBMC from healthy donors. This frequency is further increased on DTC TILS ( Figure 26A). While the same observation is made looking at the density of TIGIT on the surface of CD3 + CD4 + non-Treg cells and CD4 + Treg cells, for CD3 + CD8 + T cells the number of TIGIT molecules per cell is decreased on DTC TILS ( Figure 26B).
  • Example 23 Structural and functional epitope mapping of TIGIT and clone 31282 To further characterize and understand the interaction between anti-TIGIT mAb clone 31282 and
  • TIGIT recombinant protein the crystal structure of 31282 in complex with TIGIT was determined by X- ray diffraction.
  • TIGIT residues 23-128 was produced by Proteros Biostructures GmbH.
  • TIGIT (23-128) with N-terminal HIS-tag (thrombin cleavable) was cloned into pET15b and expressed in LB medium in BI21 (DE3) at 37 °C in inclusion bodies.
  • Inclusion bodies (IBs) were washed with buffer containing Tris/HCI pH 7.4 and Tris/HCI pH 7.4, 0.05 % Brij-35. IBs were denaturated with 6 M Gdm/HCI, 50 mM Tris pH 8.5 and 10 mM DTT.
  • Refolding was performed in 50 mM Tris/HCI pH8, 1 mM GSH, 0.5 mM GSSG, 150 mM NaCI. Refolded protein was purified on HIS-trap. The N-terminal HIS-tag was removed via Thrombin cleavage and further purification on Superdex-75 equilibrated in 50 mM Tris/HCI pH 7.5, 200 mM NaCI.
  • HEK293F cell were grown in Freestyle F17 with 1 %
  • DNA/FectoPro (FectoPro, PolyPlus) was prepared in pure F17 Medium and incubated for 10 minutes (according to PolyPlus protocol). This transfection mix was added to the cell suspension dropwise and the Booster was added immediately. 18 hrs after transfection the culture was fed with 3 g/L glucose.
  • Fab-TIGIT complex formation purified TIGIT was mixed with purified Fab in a ratio of 1 .5:1 and the complex was purified on Superdex-200 equilibrated in 20 mM Tris pH 8, 100 mM NaCI.
  • the Fab-TIGIT complex was concentrated to 35 mg/ml for crystallization.
  • the Fab-TIGIT complex was crystallized at 277K using the vapour diffusion method by mixing 0.1 ⁇ protein solution (35.3 mg/ml in 20mM TRIS pH 8,0; 100 mM NaCI) in a 1 :1 ratio with reservoir solution (0.10 M Sodium cacodylate pH 6.00; 15% (w/v) PEG4000). Crystals were cryo-protected by immersing them in reservoir solution with 25 % glycerol added.
  • a cryo-protocol was established using Proteros Biostructures GmbH Standard Protocols. Crystals have been flash-frozen and measured at a temperature of 100 K. X-ray diffraction data was collected from Fab IGIT complex crystals at the SWISS LIGHT SOURCE (SLS, Villigen , Switzerland) using cryogenic conditions. The crystals belong to space group P1 . Data were processed using the programmes XDS and XSCALE. Data collection and processing statistics can be found in Table 22.
  • phase information necessary to determine and analyse the structure was obtained by molecular replacement.
  • a previously solved structure of Fab was used as a search model.
  • Subsequent model building and refinement was performed according to standard protocols with the software packages CCP4 and COOT.
  • CCP4 and COOT the software packages
  • TLS refinement (using REFMAC5, CCP4) has been carried out, which resulted in lower R-factors and higher quality of the electron density map.
  • Automatically generated local NCS restraints have been applied (keyword “ncsr local” of newer REFMAC5 versions).
  • the ligand parameterisation and generation of the corresponding library files were carried out with CHEMSKETCH and LIBCHECK (CCP4), respectively.
  • the water model was built with the "Find waters" algorithm of COOT by putting water molecules in peaks of the Fo-Fc map contoured at 3.0 followed by refinement with REFMAC5 and checking all waters with the validation tool of COOT.
  • the criteria for the list of suspected waters were: B-factor greater 80 A2, 2Fo-Fc map less than 1 .2 ⁇ , distance to closest contact less than 2.3 A or more than 3.5 A.
  • the suspected water molecules and those in the ligand binding site (distance to ligand less than 10 A) were checked manually.
  • the final complex structure was refined with PHENIX. We chose the refinement parameter including XYZ coordinates, Real space, Individual B-factors and Group B- factors.
  • the heavy and light chains of the human Fab antibody fragment show the typical folding of human antibodies ( Figure 27A). There are two hetero-trimers in the asymmetric unit with basically the same overall conformation.
  • the model comprises residues 23 to 128 of TIGIT, residues 1 to 224 of the heavy chain of clone 31282 and residues 1 to 214 of the light chain of clone 31282.
  • One short loop region of the heavy chain is not fully defined by electron density and has thus not been included in the model.
  • Clone 31282 heavy chain interacts with different regions of TIGIT with CDR H1 Tyr33 contacting TIGIT on residue Leu73; with CDR H2 Val50, Ser54 and Ser57 contacting TIGIT on residue Leu73; with CDR H3 Asp102, Tyr103 and Trp104 contacting TIGIT on residue Gln56, Ile68, Leu73 and His76.
  • Contact residues were defined as each amino acid meeting each of the following criteria: (i) it has a calculated binding free energy contribution greater than 0.3 kcal/mol, (ii) it has an experimental averaged B-factor lower than the mean B-factor of all residues in the X-ray structure, (iii) it makes at least 3 pairs of heavy-atom interatomic contacts with antibody atoms at a distance less than or equal to 4.0 Angstroms, (iv) it does not make only solvent-exposed hydrogen bond or ionic interactions, (v) if it is a non-aromatic polar residue (Asn, Gin, Ser, Thr, Asp, Glu, Lys, or Arg), it makes at least one hydrogen bond or ionic interaction with the antibody.
  • Table 24 Summary of epitope residues of TIGIT and corresponding paratope residues on the light chain of clone 31282
  • Example 24 Competition assay between a-TIGIT clones 31282 and 32959.
  • Anti-TIGIT antibody clone 32959 of human lgG1 isotype was produced in HEK cells and purified as described in Example 17 above.
  • Jurkat cells overexpressing human TIGIT (Jurkat-hTIGIT) were collected and distributed at 5.10 4 cells/well and incubated with antagonist a-TIGIT clone 31282 at the following concentrations: OnM (No Ab), 0.08nM, 0.16nM, 0.8nM and 8nM that represent a range of concentration from 0 to 100 times the Kd of this clone. Excess of antibody was washed, and cells were incubated with decreasing concentration (8; 4; 2; 1 ; 0.5; 0.25; 0.125; 0.062; 0.031 ; 0.016; 0.008 and 0.004 nM) of directly coupled (AF647) anti-TIGIT clone 32959 for 30 min at 4°C.
  • Geometric mean fluorescence intensity was analysed using LSR BD Fortessa. Cell binding was recorded as the median florescence intensity of AF647.
  • EC50 binding of clone 32959 the half-maximal concentration of binding (EC50) to hTIGIT-Jurkat was calculated using a four-variable curve-fit equation in Prism, and the obtained values are shown in Table 26 and illustrated in Fig.28. The results show a strong binding of a-TIGIT clone 32959, independently of the concentration of clone 31282, demonstrating the absence of competition with an antagonist a-TIGIT antibody.
  • Table 26 ECso concentration for binding of a-TIGIT clone 32959 to Jurkat-hTIGIT in presence of increasing concentration of antagonist a-TIGIT clone 31282
  • Example 25 Determination of pharmacokinetic profile of clone 31282 after single i.v. injection in cynomolgus monkey
  • Antibody was administered at 3 different concentrations (0.1 mg/kg ; 1 mg/kg; 10mg/kg) to 2 animals (1 male and 1 female). Blood was collected through 504 hours post-dose on Day 1 . Blood samples were processed for plasma and analyzed for concentration of a-TIGIT clone 31282 lgG1 or lgG4 using an ELISA method.
  • Plasma concentration-time data from individual animals were used to calculate toxicokinetic parameter values for a-TIGIT clone 31282 lgG1 and lgG4 after IV dosing using the intravascular model in Phoenix WinNonlin (version 6.3, Pharsight, a Certara Company, Princeton , NJ).
  • Table 27 Summary of mean Toxicokinetics parameters for a-TIGIT clone 31282 human lgG1 after i.v. bolus in Cynomolgus monkey
  • Table 28 Summary of mean Toxicokinetics parameters for a-TIGIT clone 31282 human IgG after i.v. bolus in Cynomolgus monkey
  • TIGIT expression was profiled on immune cells of Sezary Syndrome patients using the following commercial reagents: anti-CD3 Krome Orange (#B00068), anti-CD4-PE(#A07751), anti, CD8-PC7 (#737661), anti-CD56-PC5 (#A07789), anti- CD45-Pacific Blue (#A74763), anti-CD19-AF750 (#A94681 ) and anti-Vb8-FITC (#IM1233) (all from Beckman-Coulter) and anti-TIGIT-APC (clone MBSA43, ebiosciences # 17-9500-42).
  • FIG. 30A Flow-cytometry analyses of Sezary Syndrome patient samples were performed on a CytoFlex apparatus (Beckman- Coulter). Data were analyzed with FloJo software (FlowJo, LLC). A representative example is shown on Figure 30A. Gating strategy for this donor that has a malignant TCR-Vb8 clone is shown in Figure 30A with malignant cells being CD45 + CD3 + CD4 + Vb8 + and normal CD4+ T cells being CD45 + CD3 + CD4 + Vb8 " . A strong expression of TIGIT is observed on the malignant CD4 + T cells compared to the normal CD4 + T cells (respective MFI of 4987 and 999) ( Figure 30B).
  • flow cytometry analyses were performed to assess the expression of TIGIT on normal and malignant B cells in bone marrow samples from patients with CLL.
  • the samples were stained with the following antibody panel: LVD efluor 780 (eBioscience 65-0865-14), anti-CD45-BB515 (Clone HI30, BD Horizon 564585), anti-CD5-BV510 (Clone UCHT2, Biolegend 363381), anti-CD19-BV71 1 (Clone SJ25C1 , BD Horizon 563036) and anti-TIGIT-PE (Clone MBSA43, eBioscience E13456-108).
  • LVD efluor 780 eBioscience 65-0865-14
  • anti-CD45-BB515 Clone HI30, BD Horizon 564585
  • anti-CD5-BV510 Clone UCHT2, Biolegend 363381
  • anti-CD19-BV71 1 Clone SJ25C1 , BD Horizon 563036
  • FIG. 31 A representative example is shown on Figure 31 with gating strategy illustrated in Figure 31A.
  • a high proportion of malignant B-CLL cells are positive for TIGIT (75%), in contrast to normal B cells (1 %) (MFIs of 1440 and 810, respectively) (Figure 31 B).
  • tumour cells express TIGIT in specific blood cancer indications.
  • Example 27 Anti-tumour activity of anti-TIGIT antagonistic antibody in monotherapy in mouse T cell lymphoma model.
  • EL4 T cell lymphoma cells ATCC® TIB-39TM
  • EL4-mTIGIT mouse TIGIT
  • EL4-GFP a similar vector coding for GFP
  • the anti-TIGIT antibody used was a modified version of antibody 29527 (modified such that residue 27 of VH FR3 is mutated from L to V and where residue 6 of VH FR4 is mutated from M to T) and produced on a human lgG1 isotype.
  • mice were treated with 200 ⁇ g of anti-TIGIT or isotype control antibody (hlgG1 , BioXcell) by intraperitoneal injections on day 7, day 10, day 13 and day 16 after tumour innoculation. Tumor growth was monitored and tumor volumes were measured with electronic calipers three times a week from day 7 until day 26. Mice were sacrificed when tumor volume exceeded 2000 mm 3 . Tumor growth curves were statistically analyzed by a linear mixed model. Differences between treatment groups were evaluated by testing the interaction of time*treatment group.
  • anti-TIGIT or isotype control antibody hlgG1 , BioXcell
  • Figure 32 illustrates tumor growth curves in mice inoculated with EL4-mTIGIT (A-C) or EL4-GFP (D- F). Median tumor growth curves (A and D) as well as individual tumor growth curves for mice treated with hlgG1 isotype control (B and E) or antagonist a-TIGIT Ab (C and F) are represented. In mice inoculated with EL4-mTIGIT cells, there was a significant suppression of tumor growth when treated with anti-TIGIT Ab compared to isotype control treated group (p ⁇ 0.001).
  • anti-TIGIT Ab In addition to the combination of anti-TIGIT Ab with an anti-PD1 antibody (Examples 12, 13 and 14), the antitumor efficacy of an anti-TIGIT antibody was also evaluated in combination with agonist antibodies specific for co-stimulatory molecules 4-1 BB, OX40 and GITR, as well as with an antagonist antibody specific for checkpoint inhibitory molecule ICOS.
  • CT26 tumour cell line was purchased from ATCC® (CRL-2638TM).
  • Female balb/c mice of 8 weeks were subcutaneously inoculated in the right flank with 500.000 cells.
  • tumor volumes were on average around 75 mm 3
  • the anti-TIGIT antibody used was a modified version of antibody 29527 (modified such that residue 27 of VH FR3 is mutated from L to V and where residue 6 of VH FR4 is mutated from M to T) produced on a mouse lgG2a isotype, that was given at 20 ⁇ g /mouse.
  • Anti-4-1 BB (clone 3H3, BioXCell, BE0239) was given at 5 ug/mouse
  • a- OX-40 (clone OX-86, BioXCell, BE0031) was given at 20 ug/mouse
  • a-GITR (clones DTA-1 , BioXCell, BE0063) was given at 10 ug/mouse
  • a-ICOS (clone 7E.17G9, BioXCell, BE0059) was given at 200 ug/mouse.
  • Tumor growth was monitored and tumor volumes were measured with electronic calipers three times a week from day 7 until day 35. Mice were sacrificed when tumor volume exceeded 2000 mm 3 .
  • Tumor growth curves were statistically analyzed by a linear mixed model on logarithmically transformed tumor volumes. Differences between treatment groups were evaluated by testing the interaction of time*treatment group. This resulted in a good model fit for the vast majority of the data, except for very small tumor volumes (below 10mm 3 ). Therefore, these small tumor volumes were treated as missing values.
  • IC - immune checkpoint antibody
  • treatment groups were re-coded by a combination of two variables; anti-TIGIT (yes/no) and IC (yes/no).
  • a synergistic effect, on top of the additive effect of each treatment was evaluated by testing the interaction term anti-TIGIT*IC*time.
  • Fig. 33A shows median tumor growth curves per group as well as individual growth curves for mice treated by anti-TIGIT in monotherapy or in combination with anti-4-1 BB.
  • There was significant suppression of tumor growth in mice treated with anti-TIGIT + anti-4-1 BB compared to anti-TIGIT or anti-4-1 BB monotherapy (p 0.0005 and p ⁇ 0.0001 respectively).
  • the combination of anti-TIGIT and anti-4-1 BB antibodies resulted in 6/10 mice showing a complete response (where tumor is ⁇ 30mm 3 and considered as non-measurable), as compared with 1/10 or 0/10 complete response in groups treated respectively with a-TIGIT or a-4-1 BB as a single agent.
  • Fig. 33B shows median tumor growth curves per group as well as individual growth curves for mice treated by anti-TIGIT in monotherapy or in combination with anti-OX-40.
  • There was significant suppression of tumor growth in mice treated with anti-TIGIT + anti-OX-40 compared to anti-TIGIT or anti-OX-40 monotherapy (p 0.0002 and p ⁇ 0.0001 , respectively).
  • Fig. 33C shows median tumor growth curves per group as well as individual growth curves for mice treated by anti-TIGIT in monotherapy or in combination with anti-GITR.
  • the combination of anti-TIGIT and anti-GITR antibodies resulted in 6/10 mice showing a complete response as compared with 1/10 or 0/10 in groups treated respectively with anti-TIGIT or anti-GITR as a single agent.
  • Fig. 33D shows median tumor growth curves per group as well as individual growth curves for mice treated by anti-TIGIT in monotherapy or in combination with anti-ICOS.
  • the combination of anti-TIGIT and anti-ICOS antibodies resulted in 1/10 mice showing a complete response (where tumor is ⁇ 30mm 3 and considered as non-measurable), as compared with 1/10 or 0/10 in groups treated respectively with anti-TIGIT or anti-ICOS antibodies asa single agent.
  • Example 29 Activity of anti-TIGIT antagonistic antibody on ⁇ T cells ⁇ (gamma-delta, or g/d)T cells are a population of unconventional T cells with described antitumor activity (Zhao et al. 2018. J Transl Med. 16:122) and antiviral activity (e.g. CMV infection) and also have been implicated in autoimmune diseases (Malik S et al. 2016. Front Immunol. 7:14).
  • Flow cytometry analyses were performed to assess the expression of TIGIT on ⁇ T cells on PBMC freshly isolated from healthy individuals with a seronegative or seropositive status for Cytomegalovirus (CMV) (CMV status was assessed by the EFS concentrate Aquitaine, Bordeaux, France). Cells were stained per manufacturer's instruction using filtered FACS buffer (PBS + 2mM EDTA + 0,1 %BSA). Acquisition was performed on a FACS Fortessa (BD Biosciences) and analyzed with BD FACS DIVA software (BD Biosciences).
  • CMV Cytomegalovirus
  • ⁇ T cells were gated as follows: CD3 + TCRy5 + V52 ⁇ (V52 ⁇ ⁇ T cells) using the following antibodies: anti-TCR ⁇ APC, clone REA591 #130-109-280 from Miltenyi; anti-TCR V52-PE-Vio 770, clone REA771 , #130-1 1 1 -012 from Miltenyi; BV421 mouse anti-human CD3, clone UCHT1 , #560365 from BD Biosciences; Zombie Aqua Fixable viable kit, #423101 from Biolegend.
  • non-conventional V52 " ⁇ T cells express TIGIT in both CMV negative and positive human populations (anti-TIGIT, clone MBSA43, #12-98500-42 from eBioscience) (Fig. 34A).
  • V51 + ⁇ T cells anti-TCR Vd1 -FITC, clone REA173 #130- 100-532 and anti-FITC Microbeads #130-048-701 both from Miltenyi
  • total PBMC from CMV positive donors were activated with anti-V51 (10ug/ml) (clone R9.1 , #IM1761 from Beckman Coulter) and IL-15 (20ng/ml), #200-15-50UG from Peprotech), IL-2 (100U/ml, #200-02-1 MG Peprotech) was additionally added to isolated V51 + ⁇ T cells, in presence or absence of TIGIT-ligand CD155 (#9174- CD-050 from R&D Systems).
  • Fig. 34B shows a dose-dependent decrease in IFNy secretion (ELISA kit, #3420-1 h-20 from Mabtech) mediated by the addition of TIGIT-ligand CD155 (0, 0.1 , 1 and 10ug/ml) with a maximal inhibition reached at 1 ug/ml of CD155 .
  • the addition of anti-TIGIT Ab clone 31282 (10ug/ml) fully restores IFNy production to level equal or higher to the condition without CD155 ligand while human lgG1 isotype control has very limited effect.
  • Fig 34C demonstrates similar inhibitory effect mediated by CD155 (1 C ⁇ g/ml) after anti-V51 activation of total PBMC and a total restoration of IFNy secretion when a-TIGIT clone 31282 is added to the mix.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des anticorps anti-TIGIT et des fragments de liaison à l'antigène de ceux-ci qui inhibent la signalisation médiée par TIGIT, ainsi que des combinaisons comprenant lesdits anticorps ou fragments de liaison à l'antigène de ceux-ci et des procédés pour leur utilisation.
PCT/US2018/043968 2017-07-27 2018-07-26 Anticorps anti-tigit WO2019023504A1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
AU2018306463A AU2018306463A1 (en) 2017-07-27 2018-07-26 Anti-TIGIT antibodies
EP18750302.4A EP3484925B1 (fr) 2017-07-27 2018-07-26 Anticorps anti-tigit
MX2020000960A MX2020000960A (es) 2017-07-27 2018-07-26 Anticuerpos anti-tigit.
EP20173561.0A EP3719040A1 (fr) 2017-07-27 2018-07-26 Anticorps anti-tigit
EA202090309A EA202090309A1 (ru) 2018-04-20 2018-07-26 Анти-tigit антитела
US16/634,506 US20200407445A1 (en) 2017-07-27 2018-07-26 Anti-tigit antibodies
ES18750302T ES2812236T3 (es) 2017-07-27 2018-07-26 Anticuerpos anti-TIGIT
CN201880048693.8A CN110997720A (zh) 2017-07-27 2018-07-26 抗tigit抗体
JP2020527852A JP7366897B2 (ja) 2017-07-27 2018-07-26 抗ｔｉｇｉｔ抗体
KR1020207005664A KR20200100589A (ko) 2017-07-27 2018-07-26 항-tigit 항체
CA3070791A CA3070791A1 (fr) 2017-07-27 2018-07-26 Anticorps anti-tigit
BR112020001499-0A BR112020001499A2 (pt) 2017-07-27 2018-07-26 anticorpos anti-tigit
SG11202000660QA SG11202000660QA (en) 2017-07-27 2018-07-26 Anti-tigit antibodies
US16/159,506 US10329349B2 (en) 2017-07-27 2018-10-12 Anti-TIGIT antibodies
US16/413,557 US11439705B2 (en) 2017-07-27 2019-05-15 Anti-TIGIT antibodies
IL272227A IL272227A (en) 2017-07-27 2020-01-23 ANTI-TIGIT antibodies
US17/872,494 US20230190931A1 (en) 2017-07-27 2022-07-25 Anti-TIGIT Antibodies
US17/946,158 US20230181731A1 (en) 2017-07-27 2022-09-16 Anti-TIGIT Antibodies
JP2023123773A JP2023153911A (ja) 2017-07-27 2023-07-28 抗ｔｉｇｉｔ抗体

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762606159P 2017-07-27 2017-07-27
US62/606,159 2017-07-27
BE20175535 2017-07-31
EP17184102.6 2017-07-31
EP17184102 2017-07-31
BE2017/5535A BE1025333B1 (fr) 2017-07-27 2017-07-31 Anticorps anti-tigit
US201862660640P 2018-04-20 2018-04-20
US62/660,640 2018-04-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/159,506 Continuation US10329349B2 (en) 2017-07-27 2018-10-12 Anti-TIGIT antibodies

Publications (1)

Publication Number Publication Date
WO2019023504A1 true WO2019023504A1 (fr) 2019-01-31

Family

ID=65040352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/043968 WO2019023504A1 (fr) 2017-07-27 2018-07-26 Anticorps anti-tigit

Country Status (1)

Country Link
WO (1) WO2019023504A1 (fr)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019110596A1 (fr) * 2017-12-06 2019-06-13 Proimmune Limited Procédé de criblage de l'activité de polypeptides exprimés
WO2020053263A1 (fr) 2018-09-11 2020-03-19 Iteos Therapeutics S.A. Dérivés de thiocarbamate en tant qu'inhibiteurs d'a2a, composition pharmaceutique associée et combinaisons avec des agents anticancéreux
WO2020127377A1 (fr) 2018-12-21 2020-06-25 Ose Immunotherapeutics Molécule bifonctionnelle anti-pd-1/il -7
WO2020144178A1 (fr) * 2019-01-07 2020-07-16 Iteos Therapeutics Sa Anticorps anti-tigit
WO2020165374A1 (fr) 2019-02-14 2020-08-20 Ose Immunotherapeutics Molécule bifonctionnelle comprenant il-15ra
EP3798235A1 (fr) * 2019-09-24 2021-03-31 Industrial Technology Research Institute Anticorps anti-tigit et procédés d'utilisation
WO2021122866A1 (fr) 2019-12-17 2021-06-24 Ose Immunotherapeutics Molécules bifonctionnelles comprenant un variant de l'il-7
US11136384B2 (en) 2016-11-30 2021-10-05 Mereo Biopharma 5, Inc. Methods for treatment of cancer comprising TIGIT-binding agents
WO2021224438A1 (fr) 2020-05-07 2021-11-11 Institut Curie Antxr1 comme biomarqueur de populations de fibroblastes immunosuppresseurs et son utilisation pour prédire la réponse à l'immunothérapie
WO2021257124A1 (fr) 2020-06-18 2021-12-23 Genentech, Inc. Traitement avec des anticorps anti-tigit et des antagonistes de liaison à l'axe pd-1
WO2022100573A1 (fr) * 2020-11-10 2022-05-19 Lepu Biopharma Co., Ltd. Anticorps anti-tigit et leurs utilisations
WO2022112198A1 (fr) 2020-11-24 2022-06-02 Worldwide Innovative Network Procédé de sélection des thérapies optimales par points de contrôle immunitaire
WO2022117572A2 (fr) 2020-12-02 2022-06-09 Oncurious Nv Agoniste de ltbr utilisé pour la polythérapie contre le cancer
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
WO2022148781A1 (fr) 2021-01-05 2022-07-14 Institut Curie Association d'activateurs de mcoln et d'inhibiteurs de point de contrôle immunitaire
WO2022178135A1 (fr) 2021-02-17 2022-08-25 Iteos Belguim Sa Composés, compositions et procédés de traitement de ces derniers
WO2022214652A1 (fr) 2021-04-09 2022-10-13 Ose Immunotherapeutics Échafaudage pour molécules bifonctionnelles comprenant des domaines de liaison pd-1 ou cd28 et sirp
WO2022214653A1 (fr) 2021-04-09 2022-10-13 Ose Immunotherapeutics Nouvel échafaudage pour molécules bifonctionnelles présentant des propriétés améliorées
WO2023010094A2 (fr) 2021-07-28 2023-02-02 Genentech, Inc. Méthodes et compositions pour le traitement du cancer
WO2023056403A1 (fr) 2021-09-30 2023-04-06 Genentech, Inc. Méthodes de traitement de cancers hématologiques au moyen d'anticorps anti-tigit, d'anticorps anti-cd38 et d'antagonistes de liaison à l'axe pd-1
EP3985025A4 (fr) * 2019-06-13 2023-09-13 Green Cross Corporation Anticorps dirigé contre tigit et son utilisation
WO2023215719A1 (fr) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anticorps anti-tigit et leurs utilisations
US11820824B2 (en) 2020-06-02 2023-11-21 Arcus Biosciences, Inc. Antibodies to TIGIT
WO2023240058A2 (fr) 2022-06-07 2023-12-14 Genentech, Inc. Méthodes pronostiques et thérapeutiques pour le cancer
WO2024003360A1 (fr) 2022-07-01 2024-01-04 Institut Curie Biomarqueurs et leurs utilisations pour le traitement du neuroblastome
WO2024028386A1 (fr) 2022-08-02 2024-02-08 Ose Immunotherapeutics Molécule multifonctionnelle dirigée contre cd28
US11919953B2 (en) 2020-07-15 2024-03-05 Amgen Inc. TIGIT and CD112R blockade

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
WO2009036379A2 (fr) 2007-09-14 2009-03-19 Adimab, Inc. Bibliothèques d'anticorps synthétiques rationnelles et leurs utilisations
WO2010105256A1 (fr) 2009-03-13 2010-09-16 Adimab, Inc. Banques d'anticorps synthétiques, conçues de façon rationnelle, et leurs utilisations
WO2012009568A2 (fr) 2010-07-16 2012-01-19 Adimab, Llc Banques d'anticorps
WO2014179363A1 (fr) 2013-04-29 2014-11-06 Adimab, Llc Réactifs multispécificité, procédés de préparation et d'utilisation associés
WO2016028656A1 (fr) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anticorps anti-tigit
US20160176963A1 (en) 2014-12-23 2016-06-23 Bristol-Myers Squibb Company Antibodies to tigit
WO2016191643A2 (fr) 2015-05-28 2016-12-01 Oncomed Pharmaceuticals, Inc. Agents de liaison à tigit et leurs utilisations
WO2017053748A2 (fr) 2015-09-25 2017-03-30 Genentech, Inc. Anticorps anti-tigit et méthodes d'utilisation
WO2017152088A1 (fr) 2016-03-04 2017-09-08 JN Biosciences, LLC Anticorps anti-tigit

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
WO2009036379A2 (fr) 2007-09-14 2009-03-19 Adimab, Inc. Bibliothèques d'anticorps synthétiques rationnelles et leurs utilisations
WO2010105256A1 (fr) 2009-03-13 2010-09-16 Adimab, Inc. Banques d'anticorps synthétiques, conçues de façon rationnelle, et leurs utilisations
WO2012009568A2 (fr) 2010-07-16 2012-01-19 Adimab, Llc Banques d'anticorps
WO2014179363A1 (fr) 2013-04-29 2014-11-06 Adimab, Llc Réactifs multispécificité, procédés de préparation et d'utilisation associés
WO2016028656A1 (fr) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anticorps anti-tigit
US20160176963A1 (en) 2014-12-23 2016-06-23 Bristol-Myers Squibb Company Antibodies to tigit
WO2016106302A1 (fr) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Anticorps contre tigit
WO2016191643A2 (fr) 2015-05-28 2016-12-01 Oncomed Pharmaceuticals, Inc. Agents de liaison à tigit et leurs utilisations
US20160376365A1 (en) 2015-05-28 2016-12-29 Oncomed Pharmaceuticals, Inc. Tigit-binding agents and uses thereof
WO2017053748A2 (fr) 2015-09-25 2017-03-30 Genentech, Inc. Anticorps anti-tigit et méthodes d'utilisation
WO2017152088A1 (fr) 2016-03-04 2017-09-08 JN Biosciences, LLC Anticorps anti-tigit

Non-Patent Citations (34)

* Cited by examiner, † Cited by third party
Title
"GenBank", Database accession no. NM_173799
CHEW ET AL., PLOS PATHOGENS., 2016, pages 12
CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CHOTHIA ET AL., J. MOL. BIOL., vol. 227, 1992, pages 799 - 817
DE GROOT ET AL., BLOOD, vol. 112, 2008, pages 3303
DE GROOT ET AL., CLINICAL IMMUNOL., vol. 131, 2009, pages 189
ESTEP ET AL., MABS, vol. 5, no. 2, 2013, pages 270 - 278
GLEN M. CHEW ET AL: "TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection", PLOS PATHOGENS, vol. 12, no. 1, 7 January 2016 (2016-01-07), pages e1005349, XP055447824, DOI: 10.1371/journal.ppat.1005349 *
GRAHAM ET AL., J. GEN. VIROL., vol. 36, 1977, pages 59 - 74
GUEROIS ET AL., J. MOL. BIOL., vol. 320, no. 2, 2002, pages 369 - 87
HARLOW; LANE: "Antibodies, A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS, pages: 567 - 569
HOLLIGER; HUDSON, NATURE BIOTECHNOL., vol. 23, 2005, pages 1126 - 1136
JOHNSTON ET AL., CANCER CELL, vol. 26, 2014, pages 1
JOHNSTON ROBERT J ET AL: "The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+T Cell Effector Function", CANCER CELL, CELL PRESS, US, vol. 26, no. 6, 26 November 2014 (2014-11-26), pages 923 - 937, XP029111576, ISSN: 1535-6108, DOI: 10.1016/J.CCELL.2014.10.018 *
JOLLER ET AL., IMMUNITY, vol. 40, 2014, pages 569
KABAT ET AL., J. BIOL. CHEM., vol. 252, 1977, pages 6609 - 6616
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KAO; PUCK: "Genetics of somatic mammalian cells, VII. Induction and isolation of nutritional mutants in Chinese hamster cells", PROC. NATL. ACAD. SCI., vol. 60, 1968, pages 1275 - 1281
KURTULUS ET AL., J.CLIN.INVEST., vol. 276, 2015, pages 112
MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745
MALIK S ET AL., FRONT IMMUNOL., vol. 7, 2016, pages 14
MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68
MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 252
MOREA ET AL., METHODS, vol. 20, 2000, pages 267 - 279
SILVA ET AL., J BIOL CHEM., vol. 290, no. 9, 27 February 2015 (2015-02-27), pages 5462 - 5469
SOUTHWOOD ET AL., J. IMMUNOL, vol. 160, 1998, pages 3363
TATUSOVA ET AL.: "Blast 2 sequences - a new tool for comparing protein and nucleotide sequences", FEMS MICROBIOL LETT., vol. 174, pages 247 - 250
TRAMONTANO ET AL., J. MOL. BIOL, vol. 215, 1990, pages 175 - 182
URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216
WANG ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 96, 2007, pages 1 - 26
XU ET AL., PROTEIN ENG DES SEL, vol. 26, no. 10, 2013, pages 663 - 670
XU ET AL., PROTEIN ENG DES SEL., vol. 26, no. 10, 2013, pages 663 - 670
YU ET AL., NAT. IMMUNOL., vol. 10, 2009, pages 48
ZHAO ET AL., J TRANSL MED., vol. 16, 2018, pages 122

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11230596B2 (en) 2016-11-30 2022-01-25 Mereo Biopharma 5, Inc. Methods for treatment of cancer comprising TIGIT-binding agents
US11136384B2 (en) 2016-11-30 2021-10-05 Mereo Biopharma 5, Inc. Methods for treatment of cancer comprising TIGIT-binding agents
WO2019110596A1 (fr) * 2017-12-06 2019-06-13 Proimmune Limited Procédé de criblage de l'activité de polypeptides exprimés
WO2020053263A1 (fr) 2018-09-11 2020-03-19 Iteos Therapeutics S.A. Dérivés de thiocarbamate en tant qu'inhibiteurs d'a2a, composition pharmaceutique associée et combinaisons avec des agents anticancéreux
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
WO2020127377A1 (fr) 2018-12-21 2020-06-25 Ose Immunotherapeutics Molécule bifonctionnelle anti-pd-1/il -7
WO2020144178A1 (fr) * 2019-01-07 2020-07-16 Iteos Therapeutics Sa Anticorps anti-tigit
WO2020165374A1 (fr) 2019-02-14 2020-08-20 Ose Immunotherapeutics Molécule bifonctionnelle comprenant il-15ra
EP3985025A4 (fr) * 2019-06-13 2023-09-13 Green Cross Corporation Anticorps dirigé contre tigit et son utilisation
US11667709B2 (en) 2019-09-24 2023-06-06 Industrial Technology Research Institute Anti-TIGIT antibodies and methods of use
TWI764291B (zh) * 2019-09-24 2022-05-11 財團法人工業技術研究院 抗tigit抗體及使用方法
EP3798235A1 (fr) * 2019-09-24 2021-03-31 Industrial Technology Research Institute Anticorps anti-tigit et procédés d'utilisation
WO2021122866A1 (fr) 2019-12-17 2021-06-24 Ose Immunotherapeutics Molécules bifonctionnelles comprenant un variant de l'il-7
WO2021224438A1 (fr) 2020-05-07 2021-11-11 Institut Curie Antxr1 comme biomarqueur de populations de fibroblastes immunosuppresseurs et son utilisation pour prédire la réponse à l'immunothérapie
US11820824B2 (en) 2020-06-02 2023-11-21 Arcus Biosciences, Inc. Antibodies to TIGIT
WO2021257124A1 (fr) 2020-06-18 2021-12-23 Genentech, Inc. Traitement avec des anticorps anti-tigit et des antagonistes de liaison à l'axe pd-1
US11919953B2 (en) 2020-07-15 2024-03-05 Amgen Inc. TIGIT and CD112R blockade
WO2022100573A1 (fr) * 2020-11-10 2022-05-19 Lepu Biopharma Co., Ltd. Anticorps anti-tigit et leurs utilisations
WO2022112198A1 (fr) 2020-11-24 2022-06-02 Worldwide Innovative Network Procédé de sélection des thérapies optimales par points de contrôle immunitaire
WO2022117572A2 (fr) 2020-12-02 2022-06-09 Oncurious Nv Agoniste de ltbr utilisé pour la polythérapie contre le cancer
WO2022148781A1 (fr) 2021-01-05 2022-07-14 Institut Curie Association d'activateurs de mcoln et d'inhibiteurs de point de contrôle immunitaire
WO2022178135A1 (fr) 2021-02-17 2022-08-25 Iteos Belguim Sa Composés, compositions et procédés de traitement de ces derniers
WO2022214653A1 (fr) 2021-04-09 2022-10-13 Ose Immunotherapeutics Nouvel échafaudage pour molécules bifonctionnelles présentant des propriétés améliorées
WO2022214652A1 (fr) 2021-04-09 2022-10-13 Ose Immunotherapeutics Échafaudage pour molécules bifonctionnelles comprenant des domaines de liaison pd-1 ou cd28 et sirp
WO2023010094A2 (fr) 2021-07-28 2023-02-02 Genentech, Inc. Méthodes et compositions pour le traitement du cancer
WO2023056403A1 (fr) 2021-09-30 2023-04-06 Genentech, Inc. Méthodes de traitement de cancers hématologiques au moyen d'anticorps anti-tigit, d'anticorps anti-cd38 et d'antagonistes de liaison à l'axe pd-1
WO2023215719A1 (fr) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anticorps anti-tigit et leurs utilisations
WO2023240058A2 (fr) 2022-06-07 2023-12-14 Genentech, Inc. Méthodes pronostiques et thérapeutiques pour le cancer
WO2024003360A1 (fr) 2022-07-01 2024-01-04 Institut Curie Biomarqueurs et leurs utilisations pour le traitement du neuroblastome
WO2024028386A1 (fr) 2022-08-02 2024-02-08 Ose Immunotherapeutics Molécule multifonctionnelle dirigée contre cd28

Similar Documents

Publication Publication Date Title
US10329349B2 (en) Anti-TIGIT antibodies
WO2019023504A1 (fr) Anticorps anti-tigit
AU2016331052B2 (en) Anti-TIGIT antigen-binding proteins and methods of use thereof
JP7512290B2 (ja) 抗ｔｉｇｉｔ抗体
US11208487B2 (en) Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies
KR20190039421A (ko) 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
EP3661966A1 (fr) Anticorps anti-cd39, compositions comprenant des anticorps anti-cd39 et méthodes d'utilisation d'anticorps anti-cd39
JP2020511947A (ja) 抗ニューロピリン抗原結合タンパク質およびその使用の方法
JP2019537449A (ja) 抗ｇｉｔｒ抗原結合タンパク質およびその使用方法
EA045372B1 (ru) Анти-tigit антитела
IL301513A (en) Antibodies able to bind to ROR2 and bispecific antibodies that bind to ROR2 and CD3

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2018750302

Country of ref document: EP

Effective date: 20190213

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18750302

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3070791

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020527852

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020001499

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018306463

Country of ref document: AU

Date of ref document: 20180726

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112020001499

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200123